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Bayesian Modeling Strategies for Complex Data Structures, with Applications to
Neuroscience and Medicine
Feihan Lu
Bayesian statistical procedures use probabilistic models and probability distributions to
summarize data, estimate unknown quantities of interest, and predict future observations.
The procedures borrow strength from other observations in the dataset by using prior distri-
butions and/or hierarchical model specifications. The unique posterior sampling techniques
can handle different issues, e.g., missing data, imputation, and extraction of parameters
(and their functional forms) that would otherwise be difficult to address using conventional
methods. In this dissertation, we propose Bayesian modeling strategies to address various
challenges arising in the fields of neuroscience and medicine. Specifically, we propose a
sparse Bayesian hierarchical Vector Autoregressive (VAR) model to map human brain con-
nectivity using multi-subject multi-session functional magnetic resonance image (fMRI) data.
We use the same model on patient diary databases, focusing on patient-level prediction of
medical conditions using posterior predictive samples. We also propose a Bayesian model
with an augmentedMarkov ChainMonte Carlo (MCMC) algorithm on repeat Electrical Stim-
ulation Mappings (ESM) to evaluate the variability of localization in brain sites responsible
for language function. We close by using Bayesian disproportionality analyses on sponta-
neous reporting system (SRS) databases for post-market drug safety surveillance, illustrating
the caution required in real-world analysis and decision making.
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Introduction
Bayesian statistical procedures use probabilistic models and probability distributions to sum-
marize data, estimate unknown quantities of interest, and predict future observations (Gel-
man et al. 2014, Green et al. 2015). Bayesian procedures can handle datasets with complex
structures using various multilayer modeling strategies. By using prior distributions and/or
hierarchical model specifications, the procedures allow partial pooling of data and parameters,
leading in general to greater accuracy than methods that either admit no pooling (e.g., subject
specific estimates) or demand complete pooling (e.g., estimates that average over all sub-
jects). Further, Bayesian posterior sampling techniques can handle missing data imputation,
and extraction of parameters (and their functional forms) more conveniently than conventional
methods (e.g., maximum likelihood).
Over the past few decades, Bayesian methods have been widely applied in many fields,
including economics (Greenberg 2012, Karlsson 2015), social science (Jackman 2009), ecol-
ogy (McCarthy 2007) and healthcare (Spiegelhalter et al. 2004, Aven and Eidesen 2007). In
healthcare practice, the sample size to estimate certain quantity of interest may be too small
to draw accurate medicine conclusions. For example, the occurrence of a rare disease could
be a very small number and thus treatment for such disease could be vague. This is similar
for personalized treatment, where targeted medical decisions could be made based on limited
historical information. One remarkable advantage of Bayesian methods in these settings is
that it is able to borrow information from other less rare diseases or from other patients with
more historical information, leading to deeper understanding of the underlying rare disease or
more effective treatment for individual patients. Further, in neuroscience, the data could have
complex structure that requires flexible modeling strategy to extract the desired information.
1
In this dissertation, we use Bayesian methodology to construct new models and methods for
analyzing complex data from neuroscience and medicine.
In Chapter 1, we propose a sparse Bayesian hierarchical Vector Autoregressive (VAR)
model to map human brain connectivity. In particular, we focus on resting state functional
connectivity, using multi-subject multi-session functional magnetic resonance image (fMRI)
time series data. The biggest challenge of this application is the complex structure of the
dataset, which consists of multivariate time series observed for many subjects, with each
subject observed at several occasions. Our model uses a flexible model specification to incor-
porate such complex data structure, allowing the decomposition of functional connectivity
into its group, subject, and subject-session components and estimation of between subject and
between session variabilities. This provides us with the opportunity to investigate whether
connectivity is consistent across subjects and replications, something that to date has not
been extensively explored. By adopting the doubly adaptive Elastic-net prior (Gefang 2014),
our model induces sparsity in parameter estimation without assuming special structure for
the error covariance matrix. Using parameter-expanded Gibbs sampler (Higdon 1998), our
model greatly speeds up computation and can handle a larger number of brain regions than in
previous works. A comprehensive simulation study and a real data example from the Human
Connectome Project database (http://www.humanconnectomeproject.org) are used to
illustrate the performance of our model.
In Chapter 2, we use the same sparse Bayesian hierarchical VAR model employed in
Chapter 1 on the patient diary databases, focusing on patient-level prediction of medical
conditions using posterior predictive samples. In many patient diary databases, longitudinal
data on the activities of daily living, moods, personal habits, diseases or disorders of individual
patients are collected, based on which patient-level prediction is often conducted. Existing
studies commonly fit separate VARmodels for each individual patient. While thismethodmay
be sufficient for patients who have an adequate number of observations, it may fail to provide
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reliable prediction for others who may have a significantly smaller number of observations
due to late participation or dropout in the study. Using the hierarchical model structure
which allows partial pooling among subjects, we improved predictive performance for future
observations compared to existing models, especially for subjects with a small number of
observations. Our approach also enables estimation of between-subject heterogeneity by
contrast with ad-hoc approaches such as the clustering analysis on the subject-specific VAR
coefficient estimates. We apply the model to two diary datasets to predict 1). substance use
craving, negative affect and tobacco use among college students and 2). functional somatic
symptoms (FSS) and psychological discomforts among subjects who had persistent FSS’s.
In Chapter 3, we propose a novel Bayesian model for repeat Electrical Stimulation Map-
pings (ESM) to quantify the change in localization of the brain regions responsible for
language function over a long period of time. The major challenges in repeat ESM’s are
1). the discrepancy in number of sites mapped across different occasions leading to missing
observations in the dataset and 2). unknown matching of sites between the mappings. We
adopt an augmented Markov Chain Monte Carlo (MCMC) posterior sampling procedure to
quantify the change of locations in these sites over time, impute unobserved sites and provide
a probabilistic solution for matching the sites across occasions. We use this chapter to illus-
trate the strength of the Bayesian methods in incorporating different data needs and recover
parameters that are generally difficult to extract by conventional methods.
Due to the aforementioned advantages, Bayesianmodels have been applied to a wide range
of healthcare data analysis. Nevertheless, application of thesemodeling strategies to realworld
data requires great cautions in terms of what data should be used and what interpretations can
be made of the results. In Chapter 4, we provide a note to demonstrate potential pitfalls in
applying Bayesian methods to real data problems, in particular, the application to large-scale
spontaneous reporting system (SRS) databases for post-market drug safety surveillance. In
such data mining problems, Bayesian disproportionality analyses emerged to identify signals
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of safety concerns of a target drug by comparing it to the background reporting experience
across all other drugs in the database. Head-to-head comparisons of the target drug to a single
reference drug are also not uncommon. Using empirical approach (i.e., by comparing the two
backgrounds for all drug-adverse event-combinations in the Food and Drug Administration
SRS database), we find that the latter comparison using a single drug as background generally
yields smaller disproportionality metrics, masking the true safety signaling. We therefore
use this chapter to emphasize the awareness of appropriate usage of Bayesian methods and
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1.1 Introduction
Functional magnetic resonance imaging (fMRI) (Ogawa et al. 1990) is a non-invasive imaging
technology widely used by neuroscientists to identify brain regions responsible for specific
functions (Friston 1994, Cohen and Bookheimer 1994, Downing et al. 2001, Beauchamp et al.
2010) and investigate the coordination, called connectivity, among distinct brain regions (He
et al. 2003, Sporns et al. 2003, Buckner et al. 2008).
Task related connectivity studies, in which subjects are exposed to one or more exper-
imental stimuli, have been used by neuroscientists to investigate, for example, interactions
among brain regions in the processing of visual information (Greicius et al. 2004, Di et al.
2015, Goghari and Lawlor-Savage 2017), verbal information (Senden et al. 2017, Kepinska
et al. 2017), and decision making (Kohno et al. 2015). Studies of resting state connectivity, in
which subjects are scanned while awake, but not explicitly tasked, are also of great interest,
in some measure due to the discovery that the amount of energy consumed by the brain
on task is only minimally greater than that consumed at rest (Raichle and Mintun 2006).
These studies (for example, Biswal et al. 1995, Gusnard and Raichle 2001, Fox et al. 2005,
Buckner and Vicent 2007, Thomas Yeo et al. 2011) have identified various combinations
of regions, called resting state networks (RSN), consistently activated while subjects are at
rest. Resting state connectivity studies are also of clinical significance. Comparisons of
fMRI scans of healthy control subjects with subjects suffering from various diseases or dis-
orders have revealed group differences in connectivity (Sporns et al. 2003, Buckholtz and
Meyer-Lindenberg 2012, Pievani et al. 2014, Iturria-Medina and Evans 2015), leading to the
development of therapeutic interventions for diseases such as Alzheimer (Petrella et al. 2011),
autism (Kennedy et al. 2006) and ADHD (Tian et al. 2006).
Various procedures have been proposed to study functional connectivity usingmultivariate
fMRI time series data (for reviews, see Margulies et al. 2010, Lee et al. 2013, Cribben and
Fiecas 2016), in which the blood oxygenation level dependent (BOLD) responses of each
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subject are recorded at V = thousands of spatial locations (voxels) and T = several hundred or
more time points separated by one or two seconds. In “static” studies, connectivity measures
for single subjects are typically computed first. Group level connectivity is then assessed by
averaging the single subject measures over sub-groups of subjects, e.g., patients or healthy
control subjects.
The contemporaneous association between the BOLD responses in different voxels (or
the average of the BOLD responses over regions of interest (ROI) composed of aggregates
of voxels) is typically used to measure single subject connectivity. Many studies have used
the cross-correlation. This is the Pearson correlation coefficient (or sometimes its Fisher z-
transformation) between voxel (or ROI) pairs. A predefined threshold value is then typically
used to categorize pairs as correlated or uncorrelated (Biswal et al. 1995, Cordes et al. 2000,
Buckner et al. 2008). Other studies have used the partial cross-correlation (typically obtained
from the sample precision matrix), the correlation between voxel (or ROI) pairs controlling
for the association due to all other voxels (or ROI’s) (Zhen et al. 2007, Dawson et al. 2016).
Cross-coherence and partial cross-coherence are, respectively, analogues of cross-correlation
and partial cross-correlation in the frequency domain. These measures have also been used in
a number of studies (Sun et al. 2004, Salvador et al. 2005, Liu et al. 2010, Peng et al. 2016).
Functional connectivity has also been studied using principal component analysis (PCA)
and independent component analysis (ICA), often in tandem, and typically applied to voxel-
level data (Kiviniemi et al. 2003, Beckmann et al. 2005, Damoiseaux et al. 2006). First, the
covariance (or correlation) matrix Σ of the NT × V data matrix, where N is the number of









iαi = 1), and C uncorrelated components (eigenvectors) corresponding to the C
largest eigenvalues are chosen; typically C is much smaller than V .
ICA is then applied to factorize the data matrix as the product of a NT ×C matrix L with
a C × V matrix Z . Typically, a pre-defined threshold is applied to each row of Z to yield
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independent clusters of “connected” voxels.
The preceding methods are easy to compute and in resting state studies, have consistently
identified RSN’s such as the motor, auditory, visual, sensory, cerebellum and default mode
networks (Biswal et al. 1995, Damoiseaux et al. 2006, Buckner et al. 2008). Cross-correlation
and cross-coherence are typically visualized using heat maps that display the significance (i.e.,
t-ratios or p-values) of the coefficients. But heat maps do not indicate themagnitude (strength)
of the association between voxels. In studies using partial cross-correlation and partial cross-
coherence, the measures are typically extracted from the sample precision matrix, which may
be poorly estimated when V is much larger than T , as is commonly the case in fMRI. While
PCA and ICA are useful exploratory procedures to discover connected ROI’s when the ROI’s
are not defined a priori, the number of components selected is arbitrary and constraining the
components to be uncorrelated may not be substantively reasonable.
Even more importantly, the procedures above have not been used to address asynchronous
connectivity, and it would be awkward to use these to address both contemporaneous and
asynchronous connectivity in a systematic way. Therefore, neuroscientists have turned to the
use of vector autoregressive (VAR) models in conjunction with Granger causality (Granger
1969, Roebroeck et al. 2005, Webb et al. 2013, D’Souza et al. 2017). While these models
are sometimes used to make inferences about effective connectivity, that is, about the effects
of neural activity in one or more brain locations on the activity in other regions (Friston
1994), temporal precedence is not in and of itself a sufficient basis for inferring causation,
and as Lindquist and Sobel (2016) have demonstrated, the common interpretation of non-
zero coefficients in VAR models as effects is generally unwarranted. Although this does not
diminish the utility of these models for studying functional connectivity, the models currently
used by neuroscientists are limited in a number of significant ways.
Previous researchers have used VAR models to analyze single subject single session or
multi-subject single session data (Deshpande et al. 2009, Schippers et al. 2011, Webb et al.
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2013, Gorrostieta et al. 2013, Chiang et al. 2016). To analyze multi-subject single session
data, a two step procedure is often used, in which VAR models are first applied to single
subject data to obtain subject-specific estimates; these estimates are then used as the basis
for group level inference. As an example, Schippers et al. (2011) are interested in whether
two regions, say A and B, have equal “influence” on one another. They use single subject
estimates to define the A-to-B “influence” and the B-to-A “influence” and they construct a
t-test for the null hypothesis that the mean A-to-B “influence” is equal to the mean B-to-A
“influence”. Although the two step procedure is convenient for computation, because it does
not allow information to be pooled over subjects, the subject level estimates may be highly
variable. Moreover, no insight into between subject heterogeneity is obtained.
Several authors have proposed Bayesian hierarchical VARmodels for multi-subject single
session data (Gorrostieta et al. 2013, Chiang et al. 2016). In contrast to the two step procedure,
which allows no pooling, these models allow partial pooling, resulting in more accurate
estimates of subject and group level connectivity. Estimated variances of theVAR coefficients,
which suggest substantial between subject heterogeneity, are obtained by sampling from the
posterior distribution of the variance parameters.
However, these models are also limited in several important ways. First, they can only
handle a small number of ROI’s. This forces the investigator to either focus on a few ROI’s
within a network or a handful of ROI’s spanning several networks. For example, Gorrostieta
et al. (2013) studied five regionswithin themotor network andChiang et al. (2016) investigated
six regions within several resting state networks. Second, to impose sparsity, existing models
assume the error covariance matrix is diagonal (Li et al. 2010, Gorrostieta et al. 2013, Chiang
et al. 2016). These limitations can lead an investigator to make inferences that are incomplete
and/or unwarranted.
Finally, and equally important, as evidenced by data collection efforts such as the Human
Connectome Project (www.humanconectome.org), with increasing regularity, neuroscien-
9
tists are collecting data on many subjects, with each subject observed on several occasions.
With such data, one can ask whether the variability in brain activity is due primarily to dif-
ferences between subjects or differences within subjects across occasions. Previous studies
have proposed a two stage procedure (similar to the aforementioned two step procedure) for
general connectivity metrics such as cross-correlations and ICA (Wang et al. 2011, Zuo and
Xing 2014, Ge et al. 2017). In this procedure, subject-session connectivity estimates are
first obtained; individual mixed effect models are then applied on each component in the
connectivity vector. While computationally simple, this approach uses the summary statistics
obtained in the first stage, rather than the original data, to estimate the parameters in the
second stage.
We propose a sparse Bayesian hierarchical VARmodel that extends existing multi-subject
Bayesian VAR models to the multi-subject multi-session case. Our model also addresses
the limitations described above. Specifically, our model allows simultaneous inference about
group level, subject level and subject-session level resting state functional connectivity, as
well as between subject and between session variabilities. By adopting the doubly adaptive
Elastic-net prior (Gefang 2014), our model induces sparsity in parameter estimation without
assuming any special structure for the error covariance matrix. Finally, using parameter-
expanded Gibbs sampler (Higdon 1998), we can study a larger number of connected ROI’s
than previous researchers could investigate. We apply our model to data from the Human
Connectome Project to investigate resting state functional connectivity between 15 ROI’s
across 7 brain networks. Our unique modeling approach decomposes functional connectivity
into group, subject, and session components, letting us investigate whether connectivity is
consistent across subjects and replications, an important issue that has not yet been extensively
explored. We find distinct interregional connections both within and between these brain
networks and greater heterogeneity between subjects than within subjects over sessions.
We proceed as follows. Section 1.2 describes the proposed Bayesian model. Section
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1.3 describes a simulation study to investigate the performance of the model under different
scenarios and compares it to the two stage procedure described above. Section 1.4 illustrates
the model with a real example from the Human Connectome Project. Section 1.5 concludes.
1.2 Method
We extend the work of Gefang (2014), who constructed a Bayesian VAR model using a
doubly adaptive Elastic-net prior to induce sparsity, to the multi-subject multi-session case,
allowing inference about group level, subject level and subject-session level connectivity, and
between and within subject variabilities. We use a Gibbs sampler with parameter expansion
(Higdon 1998, Gelman et al. 2014) to reduce correlations among parameters and speed up
convergence, allowing us to simultaneously study more ROI’s than in previous research using
VAR models.
1.2.1 A Bayesian hierarchical sparse VAR model
For subject i ∈ {1, ...N} during period t ∈ {1, ...,T} of session s ∈ {1, ..., S}, let yistr
denote the average value (taken over the voxels in the ROI) of the BOLD responses in ROI




Aisl yis,t−l,. +  ist., (1.1)
where Aisl, l = 1, ..., p is a R × R coefficient matrix representing the lag-l association among
the BOLD responses for subject i in session s, and  ist ., t = p + 1, ...,T , are independent
and identically distributed (i.i.d.) multivariate normal with mean 0 and precision matrix Ω:
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where ⊗ denotes the Kronecher product, IR is an identity matrix of order R,
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The coefficient vector wis for the i-th subject and the s-th session is composed of three parts:
wis = w + vi + uis, (1.3)
where w is the group level coefficient vector, vi is the subject deviation vector and uis is the
subject-session deviation vector.
For the group level coefficient vector w, we use the doubly adaptive Elastic-net prior
proposed by Gefang (2014),
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2p, depends on the error precision matrix Ω:
















M = IRp ⊗ Ω−1. (1.8)
The collection of hyperparameters λ21,k and λ2,k, k = 1, ..., R
2p, are assumed to follow two
independent gamma distributions with known parameters:
λ21,k ∼ Γ(µ1, ν1), (1.9)
λ2,k ∼ Γ(µ2, ν2), (1.10)










2µ x, x > 0, µ > 0,
ν > 0, where µ and ν are, respectively, the mean and degrees of freedom (df). Here, λ1,k
and λ2,k represent, respectively, the L1 and L2 tuning parameters for the k-th component of
w. It can be shown that the conditional prior for each of the components of w given the
error precision matrixΩ is composed of a normal distribution and a Laplace distribution with
individual shrinkage parameters, that is, this prior is equivalent to theElastic-net regularization
with component-wise shrinkage. Note that conditioning on the error precision matrix Ω is
important as it ensures the posterior distribution for each of the components of w is unimodal
(Park and Casella 2008).
For the subject and subject-session deviations, we apply conjugate i.i.d. priors with mean
0 and diagonal precision matrices Θv and Θu:




, i = 1, ..., N, (1.11)




, i = 1, ..., N, s = 1, ..., S, (1.12)
where the diagonal elements of Θv and Θu, respectively, are θvk and θuk, k = 1, ..., R2p,
assumed to follow independent gamma distributions:
θvk ∼ Γ(k1, s1), k = 1, ..., R2p, (1.13)
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θuk ∼ Γ(k2, s2), k = 1, ..., R2p, (1.14)
where k1, s1 and k2, s2 are the known mean and df in (1.13) and (1.14), respectively. We
assume the group level coefficients, subject level coefficients and the subject-session level
coefficients are independent of each other given the hyperparameters.
Finally, for the error precision matrix Ω we assume a conjugate Wishart hyperprior:
Ω ∼Wishart(K, ν), (1.15)
where K and ν are the known R × R scale matrix and degrees of freedom (i.e., the mean and
variance of Ω increases as ν increases).
1.2.2 Posterior sampling and posterior inference
WeuseMarkovChainMonteCarlo (MCMC) to generate draws from the posterior distribution,
specifically, a Gibbs sampler with parameter expansion (Gelman et al. 2014). For hierarchical
regression models the sampler can be very slow if there is strong dependence between the
coefficients and their variance parameters. In our model, vi and Θv (and uis and Θu) are
dependent: when the current draw of Θv is large, the next draw of vi will be small, making
the next draw of Θv even larger, and so on. Thus the sampler can take a long time to cover
the entire parameter space, resulting in slow convergence.
Using parameter expansion allows us to reduce the dependence among parameters and
speed up convergence. Specifically, we add component-wise multiplicative factors α to vi
and β to uis (i.e., multiply αk with vik and βk with uisk, k = 1, ..., R2p), where
α ∼ MVN(0, aIR2p), (1.16)
β ∼ MVN(0, bIR2p), (1.17)
and a and b are known constants. When the current draw of Θv is large, the next draw of vi
will be small, but the next draw of α will be large (see the conditional distribution of α in
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Appendix A), resulting in the next draw of vi in a normal range (similarly for uis and Θu).
That is, the expanded parameterization allows the Gibbs sampler to move in more directions
and avoid getting stuck.
The subject and subject-session deviation parameters are now
v∗i = α ∗ vi, (1.18)
u∗is = β ∗ uis, (1.19)
and the diagonal elements of the precision matrices are
θ∗vk = α
−2




k θuk, k = 1, ..., R
2p. (1.21)
In addition to parameter expansion, to speed up convergence, we useMethod-of-Moments-
like estimates as initial values for the posterior sampling. After obtaining the posterior
samples, we use the posterior modes and posterior medians, respectively, to estimate the
group level coefficients and the other parameters. Using posterior modes for the group level
parameters induces sparsity and gives estimates equal to those obtained using penalized
likelihood methods such as the Lasso (Genkin et al. 2007, Park and Casella 2008). Using
posterior medians for other parameters increases robustness. We use the values with the
highest empirical density to obtain the posterior modes. Finally, we use the AIC as a criterion
to select the optimal order of the VAR model. See the Appendix A for the derivation of the
initial values and the full conditionals used in the Gibbs sampler.
1.3 Simulation Studies
1.3.1 Simulation studies of the Bayesian model
We conduct a simulation study to investigate the behavior of our model. We vary 3 factors:
1) sample size (N = 5, 50, 100, 500), 2) the ratio of the standard deviations of the subject
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deviations and the subject-session deviations ( f =.5, 1, 2), 3) the magnitude and structure
of the error covariance matrix, including high and low noise levels and block diagonal and
diagonal structures. We consider 4 cases, all with T = 200 time points, R = 5 regions,
S = 4 sessions, and p = 2 lags. We assume normal subject-session specific VAR models
with coefficients wis = w + vi + uis, i = 1, . . . , N, s = 1, . . . , S, and 70% of the group level
coefficients w are set to zero, with the remainder drawn from the N(0.112, 0.092) distribution.
1. Cases 1a-1d; f = 1, N = 5 (1a), 50 (1b), 100 (1c), 500 (1d). The subject deviations in
vi and the subject-session deviations in uis are each drawn from the N(0, 0.0672), i =
1, . . . , N, s = 1, . . . , S. The error covariance matrix Ω−1 is drawn from a Wishart
distribution with 10 degrees of freedom and a symmetric Toeplitz scale matrix with
diagonal elements equal to 0.2.
2. Cases 2a-2d; f =2, N = 5 (2a), 50 (2b), 100 (2c), 500 (2d). vi and uis are, respec-
tively, drawn from the N(0, 0.092) and the N(0, 0.0452) distributions, i = 1, . . . , N, s =
1, . . . , S. Ω−1 is as in case 1.
3. Case 3a-3d; f =0.5, N = 5 (3a), 50 (3b), 100 (3c), 500 (3d). vi and uis are, respec-
tively, drawn from the N(0, 0.0452) and the N(0, 0.092) distributions, i = 1, . . . , N, s =
1, . . . , S. Ω−1 is as in case 1.
4. Cases 4a-4d; f =1, N = 5. In cases 4a and 4b, the error covariance matrices are drawn
fromWishart distributions with 10 degrees of freedom and Toeplitz scale matrices with
diagonal elements equal to 0.3 (4a) and 0.1 (4b). In case 4c, the error covariance matrix
is block diagonal and in case 4d diagonal, with elements equal to 2; for both these cases,
vi and uis, i = 1, . . . , N, s = 1, . . . , S, are as in case 1.
For each case, we generated 100 repetitions using the R package ‘sparsevar’ (https:
//cran.r-project.org/web/packages/sparsevar/index.html), and we fit our VAR
model with orders of p=1, 2 and 3 to the simulated data. We use p=2 to investigate the recovery
of the parameters and p=1 and 3 to investigate whether the AIC selects the correct order. The
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entire simulation procedure was implemented in R. The computations were performed using
the Gibbs sampler strategy with expanded parameterization. For each repetition, we ran
30,000 iterations across 4 chains, using the first 15,000 iterations as warm-up; the next 15,000
iterations were thinned, keeping every 60-th iteration, yielding 250 posterior samples per
chain (for cases with N=500, we ran 40,000 iterations and used the last 20,000 iterations,
keeping every 80-th iteration, to ensure mixing of the chains). All chains mixed well. For
details about the generation of the error covariance matrices, see the Appendix A.
1.3.1.1 Parameter recovery
For each component of the group level connectivity parameters (w), the subject deviations
(v = {vi, i = 1, . . . , N}), the subject-session deviations (u = {uis, i = 1, . . . , N, s = 1, . . . , S}),
the standard deviation of the subject deviations (sdv = {θ∗
vk
− 12 , k = 1, . . . , R2p}) and the
standard deviation of the subject-session deviations (sdv = {θ∗uk−
1
2 , k = 1, . . . , R2p}), we
estimate the mean square error (MSE) using the 100 repetitions. We then average the
estimates over the components of w, v, u, sdv and sdu, respectively, obtaining estimated
average MSE’s (AMSE) for w, v, u, sdv and sdu (the number of components for w, sdv
and sdu is 50 and for v and u are 50N and 200N , respectively). Figure 1.1 displays the
MSE’s under all cases, with each boxplot representing the distribution of the MSE’s for all
components in w, v, u, sdv and sdu under a particular case. Columns 1-5 in Table 1.1 report
the estimated AMSE’s for all cases using our model.
Inspection of Figure 1.1 and Table 1.1 indicates that as N increases, the MSE’s of the
components of w, sdv and sdu become close to 0 in all cases, demonstrating that our model
recovers these parameters well: this is due to the large sample consistency of the Bayesian
estimates (Gelman et al. 2014). The number of parameters in v and u increases with N ,
so the property of large sample consistency does not hold for v and u. Nevertheless, the
estimated AMSE’s for these parameters also decreases as N increases. Further, results for












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.1: MSE’s for the components of the group level connectivity parameters (w), the subject
deviations (v), the subject-session deviations (u), the standard deviation of the subject deviations (sdv)
and the standard deviation of the subject-session deviations (sdu) for all cases using the Bayesian
model. Each boxplot represents the distribution of the MSE’s for all components in w, v, u, sdv and
sdu for a particular case.
determinant of model performance.
To assess the coverage of the 95% equal-tailed Bayesian credible intervals (based on the
2.5-th and 97.5-th posterior quantiles), we use the estimated coverage probability, based on
the 100 repetitions. Figure 1.2 displays the coverage probabilities for each of the components
in w, sdv and sdu under cases 1a-1d. (Although we would have preferred to use more
repetitions, limited access to computational resources prevented us from doing so. Therefore,
in addition to the estimate, displayed as a black dot in Figure 1.2, we also display a blue line at
the value .95 and a blue band symmetric about .95 with a length of 2 standard deviations; the
standard deviation (.021) is based on 100 draws from a binomial distribution with probability
.95.) Black dots within the blue band are indicative of a coverage probability close to the
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nominal level. The index of the panel for w is sorted by the true values of the components of
w (from smallest to largest), so the first 36 indices correspond to 0 coefficients in w. There is
no sorting for sdv and sdu since the true values are the same for each of the components.
Figure 1.2: Coverage probabilities (black dots) of the 95% equal-tailed Bayesian credible intervals
for the components of the group level connectivity parameters (w, column 1), the standard deviation
of the subject deviations (sdv, column 2) and the standard deviation of the subject-session deviations
(sdu , column 3) under cases 1a -1d (row 1-4). The index for w is sorted from smallest to largest by
the true value of the components of w, so the first 36 indices correspond to 0 coefficients in w. There
is no sorting for sdv and sdu.
Since 95% is the target level, we would expect about 2-3 of the black dots to fall outside of
the blue bands. However, as sample size N increases, the number of overcovered parameters
decreases but the number of undercovered parameters does not. We suspect this is due to two
factors: 1) the tendency, reported in previous studies (Agresti and Min 2005, Zhang 2006,
20
Figure 1.3: AIC’s obtained by fitting VAR models with order p=1, 2 and 3 under cases 1a-1c. Each
pink line in the plots represents one repetition.
Fraser 2011), for Bayesian credible intervals to undercover, and 2) the sample sizes here. To
investigate this more thoroughly, we need to examine larger sample sizes, and to do so, we
need to employ a more sophisticated computational strategy (such as the consensus Monte
Carlo algorithm (Scott et al. 2013)).
1.3.1.2 Recovery of model order using AIC
We used AIC to select the order p for the VAR model. AIC recovered the corrected order
(p=2) 100% of the time for every case. Figure 1.3 shows the boxplots of AIC’s for p=1, 2 and
3 under cases 1a-1c.
1.3.2 Comparative study with a two stage procedure
Next, we compare the performance of our model with an analogous two stage procedure
proposed for general functional connectivity metrics. Specifically, we first estimate individual
VAR models for each subject and session to obtain subject-session specific MLE’s: wˆis, i =
1, . . . , N, s = 1, . . . , S, and we then fit a mixed effect model for each component of wˆis:
wˆisk = wk + vik + uisk, k = 1, . . . , R2p, i = 1, . . . , N, s = 1, . . . , S (1.22)
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where wk is the fixed effect, vik ∼ N(0, σ2vk), i.i.d., is the random effect for subject i,




uk are, respectively, the between subject and between session variabilities.
1.3.2.1 Parameter recovery
Columns 6-10 in Tables 1.1 display the estimated AMSE’s using the two stage method,
and Columns 11-15 display the relative reduction in these for the Bayesian model, which
outperforms the two stage procedure for almost all parameters across all cases. The reduction
in the estimated AMSE is about 30% for the group level connectivity parameters (w), 6%
for the subject deviations (v), 60% for the subject-session deviations (u), 8% for the standard
deviation of the subject deviations (sdv) and 70% for the standard deviation of the subject-
session deviations (sdu). For the coverage probability, neither method reaches the nominal
level even for N=500 (the two stage method has an even lower coverage probability for w),
but about 80% of the Bayesian credible intervals are shorter than those given by the two stage
procedure. The two stage procedure does not provide range estimates for sdv and sdu.
Figures 1.4 and 1.5 display, respectively, boxplots of the estimates obtained in the 100
repetitions for each component of the group level connectivity parameters (w), the subject
deviations (v) and the subject-session deviations (u) for cases 1a (N=5) and 1c (N=100) for
the Bayesian and two stage methods. When N is small, the variance for the estimates of the
coefficients in w is smaller under the Bayesian model, especially for coefficients whose true
values are 0, due to the shrinkage imposed by the Elastic-net prior. This is also true for v
and u, due to the pooling effect of the Bayesian model, which pools over subjects, sessions
and components in the parameter vectors; the two stage procedure only pools over subjects
and sessions. As N increases, both models recover parameters in w, as these parameters are
consistently estimated under both procedures. The Bayesian model outperforms the two stage
procedure for estimating v and u due to the aforementioned differences in pooling.
Figure 1.6 displays boxplots of the estimates obtained from the 100 repetitions for the
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Figure 1.4: Boxplots of estimates obtained from the 100 repetitions for each component of the group
level connectivity parameters (w), the subject deviations (v) and the subject-session deviations (u)
using the Bayesian model (left column) and the two stage procedure (right column) under case 1a
(N=5). The red dots represent the true values of the parameters. The boxplots are sorted by the true
values for better visualization.
Figure 1.5: Boxplots of estimates obtained from the 100 repetitions for each component of the group
level connectivity parameters (w), the subject deviations (v) and the subject-session deviations (u)
using the Bayesian model (left column) and the two stage procedure (right column) under case 1c
(N=100). The red dots represent the true values of the parameters. The boxplots are sorted by the true
values for better visualization.
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Figure 1.6: Boxplots of estimates from the 100 repetitions for each component of the standard deviation
of the subject deviations (sdv, row 1) and the standard deviation of the subject-session deviations (sdu,
row 2) using the Bayesian model (column 1) and the two stage procedure (column 2) under case 1d
(N=500). The red lines display the true values.
components of sdv and sdu under case 1d (N=500). With larger N , the Bayesian estimates
are close to the true values for these parameters, whereas the two stage procedure exhibits a
positive bias for sdu, due to the fact that while the Bayesian model uses the original data to
estimate these parameters, the two stage procedure uses the summary MLE’s obtained in the
first stage to estimate these parameters in the second stage.
1.3.2.2 Recovery of sparsity in group level connectivity
We also compare the two methods in terms of the recovery of zero coefficients in the group
level connectivity parameters (w) , assessed by the area under the precision-recall curve (AUC-
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PRC) (He and Garcia 2009, Powers 2011, Saito and Rehmsmeier 2015), where precision =
TP/(TP+FP), recall= TP/(TP+FN), and TP, FP and FN represent, respectively, true positives,
false positives and false negatives. We define the zero coefficients as positive, non-zero
coefficients as negative instances, and thus TP = the number of zero coefficients that are
recovered as 0, FP = the number of non-zero coefficients that are recovered as 0, and FN = the
number of zero coefficients that are recovered as non-zero. Therefore, in our case, precision
measures how many of the coefficients recovered as 0 are truly zero, and recall measures how
many of the zero coefficients are recovered as 0. A high value of the AUC- PRC indicates
good recovery of sparsity in the coefficients.
To obtain the AUC-PRC, we conduct an α-level hypothesis test (H0 : wk = 0 vs H1 :
wk , 0) for each component of the group level coefficient wk, k = 1, . . . , R2p, by looking at
whether the (1 − α) × 100% confidence interval contains 0 or not. For each value of α, this
gives a pair of precision-recall values, and varying the value of α gives the AUC-PRC. Table
1.2 displays the averaged AUC-PRC over the 100 repetitions for the two methods. We can see
that the Bayesian model outperformed the two stage procedure in most cases, demonstrating
the advantage of the Elastic-net prior in recovering sparsity in the group level coefficients.
1.4 Application: the Human Connectome Project
1.4.1 Data and the preprocessing
We apply our model to the preprocessed and artifact-removed resting state fMRI data from 50
participants as provided by the HCP820-PTN data release of the Human Connectome Project
(http://www.humanconnectomeproject.org). The data were acquired on a customized
3T Siemens connectome-Skyra 3T scanner. Participants completed two scanning sessions on
two separate days. A T1wMPRAGE structural run was acquired on each day (acquisition time
=7.6 min, TR/TE/TI = 2400/2.14/1000ms, resolution = 0.7×0.7×0.7 mm3, SENSE factor = 2,
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Table 1.2: Average area under the precision-recall curve (AUC-PRC) over the 100 repetitions.

















flip angle = 8 degree). A simultaneous multi-slice pulse sequence with an acceleration factor
of eight was used to acquire two resting state fMRI runs on each day, with each run consisted
of 1200 volumes sampled every 0.72 seconds, at 2-mm isotropic spatial resolution (acquisition
time:14 min 24 sec, TE = 33.1 ms, flip angle = 52 degree, 72 axial slices). Participants were
instructed to keep their eyes open and fixated on a cross hair on the screen, while remaining as
still as possible. Each run was minimally preprocessed, and artifacts were removed using the
Oxford Center for FunctionalMRI of the Brain’s (FMRIB) Independent Component Analysis-
based X-noiseifier (ICA +FIX) procedure. At this point in the processing pipeline, the data
acquired on each day were represented as a time series of gray ordinates, a combination of
cortical surface vertices and subcortical standard-space voxels. Each run was temporally
demeaned and variance normalized. All four runs for all subjects were fed into MELODIC’s
Incremental Group-Principal Component Analysis (MIGP) algorithm, which estimated the
top 4500 weighted spatial eigenvectors. GICAwas applied to the output of MIGP using FSL’s
MELODIC tool using six different dimensions (i.e., number of independent components: 15,
25, 50, 100, 200 and 300). Dual-regression was used to map group level spatial maps of
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the components onto each subject’s time series data. The full set of group level maps were
used as spatial regressors against each subject’s full time series (4800 volumes) to obtain
a single representative time series per IC. The functional assignment of each component
was determined using the Yeo Resting State Networks (Thomas Yeo et al. 2011), leading
to 15 ROI’s across 7 brain networks including visual, somatomotor, dorsal attention, ventral
attention, frontoparietal, default mode and cerebellum (see Figure 1.7). The 2 runs per session
for each subject are concatenated by temporal order, yielding T=2400 points per subject per
session in the analysis.
1.4.2 Hyper-parameter values, posterior sampling and order selection
We used weakly informative hyperpriors that are conjugate but almost flat on the parameter
space. In particular, the tuning parameters λ21,k and λ2,k, k = 1, . . . , R
2p, follow the Γ(1, 0.001)
and Γ(1, 0.01) distributions, respectively. The diagonal elements of Θv and Θu are follow
the Γ(1, 0.01) distribution, and the precision matrix Ω follows the Wishart(1, (R − 1)IR)
distribution. The multiplicative variables α and β follow diffuse normal distributions
MVN(0, 100IR2p).
Previous studies (Martínez-Montes et al. 2004, Valdés-Sosa et al. 2005) find that the order
of a VAR model for functional connectivity is usually quite small (1 or 2). We therefore
fitted a VAR(1) model and a VAR(2) model, using the AIC as a model selection criterion.
For each model, we ran 50,000 iterations across 3 chains, using the first 25,000 iterations as
warm-up. The second 25,000 iterations were thinned, keeping every 75-th iteration, to break
the autocorrelation in the posterior samples, yielding 250 samples per chain for posterior
inference. All 3 chains mixed well and converged to the same stationary distribution for all





nW < 1.1, where B andW are between and within
chain variances of the posterior samples (Gelman et al. 2014), with no autocorrelation in the
posterior samples. For these data, the VAR(2) model, with AIC =27245873, is marginally
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Figure 1.7: An illustration of the 15 independent components from the HCP example separated into
7 brain networks. In each panel, hot colors (yellow-to-red) indicate the spatial locations of voxels in
a single representative slice of the brain that compose the components. Rows a-g show, respectively,
components from the visual (a.1-a.4), somatomotor (b.5), dorsal attention (c.6), ventral attention (d.7),
frontoparietal (e.8-e.11), default mode (f.12-f.14) and cerebellum (g.15) networks. Images provided
by the Human Connectome Project.
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Figure 1.8: Posterior modes of the lag one (left) and lag two (right) between region group level
connectivity parameters (w); numbers 1-15 represent the 15 ROI’s and the colors of the sections
represent the 7 brain networks. The lines from the regions on the left half circle to those on the right
half circle represent the lag one or lag two coefficients, with negative coefficients colored blue and
positive coefficients red. The color scale ranges from -0.2 to 0.2.
favored over the VAR(1) model, with AIC = 27297369.
1.4.3 Findings
1.4.3.1 Group level connectivity
Figure 1.8 displays the posterior modes of the lag one and lag two between region group
level connectivity parameters (w) between the 15 ROI’s across 7 brain networks: the numbers
1-15 represent the ROI’s and the colors of the sections represent the 7 brain networks. A
curved line from region r′ on the left half circle to region r on the right half circle represents
coefficient (rr′) in the lag one (lag two) group level coefficient matrix, that is, the lag one (lag
two) association between the BOLD response in region r at time t and region r′ at time t − 1,
t = 2, . . . ,T . The blue and red lines indicate, respectively, negative and positive coefficients.
There are strong negative lag one coefficients between most of the 15 ROI’s across the
7 networks, with the strongest coefficients (below -0.12) between the 6-th ROI in the dorsal
attention network (orange section) and the 4-th ROI in the visual network (red section), the
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same 6-th ROI in the dorsal attention network and the 11-th ROI in the frontoparietal network
(green section), and the 12-th ROI in the default mode network (blue section) and the 7-th
ROI in the ventral attention network (yellow section). Moreover, there are strong positive
coefficients (above 0.08) within the visual network (red section) between the 1-st and 4-th
ROI’s and the 3-rd and 1-st ROI’s. Analogous lag two and lag one coefficients generally
have opposite signs, a common occurrence in VAR(2) models (e.g., see Davis et al. 2016).
Nevertheless, the lag two coefficients are, in most cases, smaller in magnitude than the lag
one coefficients, suggesting the associations among the 15 ROI’s are generally negative.
1.4.3.2 Subject deviations and subject-session deviations
Figures 1.9 and 1.10 display, respectively, the posterior medians of the lag one and lag two
between region subject deviations (v) for the first 16 subjects and the subject-session deviations
(u) for the first 8 subjects. Comparison of the figures indicates that the subject deviations
tend to be stronger than the subject-session deviations across different ROI’s for both lag one
and lag two coefficients. Moreover, the subject deviations differ among subjects in both lags.
For example, subjects 9 and 13 have several large positive deviations, while subjects 3 and
10 have large negative values, suggesting substantial between subject variability. In contrast,
most subject-session deviations are close to 0 (except for 1 of the first 8 subjects), suggesting
less variability within subjects across sessions.
1.4.3.3 Between Subject and Between Session Variabilities
Figure 1.11 displays the posterior medians of the variances of the between region subject
deviations (column 1), the subject-session deviations (column 2), and the intra-class corre-
lation (ICC), the proportion of the total variance represented by the variance of the subject
deviations (column 3) for lag one (row a) and lag 2 (row b) parameters. In most instances the
estimated ICC > .5, suggesting more variability in between subject connectivity than within
subject connectivity. Our findings are broadly consistent with those obtained by several pre-
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Figure 1.9: Posterior medians of the lag one (left box) and lag two (right box) between region subject
deviations (v) for the first 16 subjects. The number at the top of the chord diagram is the subject number.
The curved lines from the regions on the left half circle to those on the right half circle represent the
lag one or lag two deviations, with negative deviations colored blue and positive deviations red; the
color scale ranges from -0.13 to 0.13.
Figure 1.10: Posterior medians of the lag one (left box) and lag two (right box) between region
subject-session deviations (u) for the first 8 subjects (letters a-h) with 2 sessions (numbers 1-2). The
curved lines from the regions on the left half circle to those on the right half circle represent the lag
one or lag two deviations, with negative deviations colored blue and positive deviations red; the color
scale ranges from -0.13 to 0.13.
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Figure 1.11: Posterior medians for the variances of the between region subject deviations (column 1)
and the subject-session deviations (column 2), and the proportion of the total variance represented by
the variance of the subject deviations (column 3) for lag one (row a) and lag two (row b) parameters.
The curved lines from the regions on the left half circle to those on the right half circle represent the
lag one or lag two deviations. For columns 1 and 2, the color scale ranges from 0 to .004 and for
column 3 from 0 to 1.
vious researchers (Shehzad et al. 2009, Zhang et al. 2011, Braun et al. 2012) who used the
ICC to study the test-retest reliability of some other measures of connectivity. However, these
researchers used two stage methods to estimate the ICC. Further, interpreting the ICC as a
test-retest reliability seems inadequate in the neuroimaging context, and can lead a researcher
to inappropriately view a small ICC purely as evidence of a methodological or measurement
problem, as versus a substantive finding of interest.
1.5 Discussion
We construct a sparse Bayesian hierarchical VAR model for studying resting state functional
connectivity for multi-subject multi-session fMRI data. Our model extends existing multi-
subject single subject Bayesian VARmodels to allow simultaneous inference regarding group
level, subject level and subject-session level connectivity. In particular, our model allows us
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to systematically address an important question: Is the major portion of variability in resting
state neural activity due to differences between subjects or differences within subjects? In
addition, our computational strategy allows us to consider more subjects and ROI’s than
previous researchers could handle, and we relax the assumption in previous work, used to
induce sparsity, of a diagonal error covariance matrix.
As demonstrated in our simulations, the model also improves on two stage procedures
for connectivity metrics in which single subject models are estimated in a first step, then
pieced together in a second step. The simulations also indicate that model estimates are quite
accurate across a wide variety of conditions, including in small samples. However, there is a
tendency for the equal-tailed credible intervals to undercover, as illustrated in Figure 2.
We study resting state data for 50 subjects from the Human Connectome Project, applying
our model with 15 ROI’s spanning 7 brain networks. Based on the AIC, we selected a VAR(2)
model. We find negative associations between ROI’s in the dorsal attention network and the
visual and frontoparietal networks, and ROI’s in the default mode network and the ventral
attention network. Key to our approach is the decomposition of functional connectivity into
group, subject, and session components allowing us to study differences within and between
subjects in functional connectivity. We find greater variability between subjects than within
subjects across sessions separated by a day, suggesting the major source of differences in
human brain connectivity is due to differences among subjects.
In future work, we intend to increase the computational capacity of the model. Using
parallel computing techniques such as the consensus Monte Carlo algorithm (Scott et al.
2013) in conjunction with our parameter expanded Gibbs sampler will allow us to work
with more ROI’s and subjects. Increasing the number of ROI’s will allow us to 1) subdivide
existing regions and assess whether the connections among regionswe have discovered require
additional refinement, and 2) extend the number of regions under investigation to a whole
brain ROI model, allowing us to potentially discover new connections between regions and
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networks. The ability to handle larger samples will allow us to estimate parameters more
reliably. It will also allow us to better differentiate among types of individuals, e.g., healthy
controls and autistic individuals, and more generally allow for the exploration of sub-group
differences, e.g., men and women.
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Appendix A
Appendix to Chapter 1
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A.1 Initial values
We use Method-of-Moments-like estimates as initial values to speed up posterior sampling.
Specifically, we first obtain the maximum likelihood estimates (MLE’s) of the subject-session








We then use these MLE’s to form initial values for the group level coefficient parameters,















(wˆis − wˆ), i = 1, . . . N,
uis
0 = wˆis − wˆ − vˆi, i = 1, . . . N, s = 1, . . . , S.
Using these initial values reduces the computational time by 60%.
A.2 Full conditional distributions
To draw from the posterior distribution using the Gibbs sampler, one draws each parameter
from its conditional distribution, given all other parameters at their current values. Let g(·)
denote the conditionals of one parameter given the others. We now give the full conditionals
for all parameters:






















⊗ Ω (wˆis − α ∗ vi − β ∗ uis)
]
,
where wˆis is the MLE given by (A.1);
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,
where Diag(·) represents assigning the R2p vector on a diagonal matrix;




























(wˆis − w − α ∗ vi)
]
;




























(wˆis − w − β ∗ uis)
]
;
































(wˆis − w − α ∗ vi)
]
;
















and vnk is the k-th component of vi;
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and uisk is the k-th component of uis;




, k = 1, ..., R2p, where
νλ1,k = ν1 + 2,
µλ1,k =











, k = 1, ..., R2p, where







and wk is the k-th component of w;
10. g (Ω) = Wishart(SΩ, νΩ), where







Sis + K−1 + 2QQT
]−1
,
Sis = (Yis −WisHis)(Yis −WisHis)T
is the residual matrix of the i-th subject and the s-th session,
Yis =
(
yis,p+1,. · · · yisT .
)
is a R × (T − p) matrix,
Wis = vec−1 (w + α ∗ vi + β ∗ uis) ,
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where vec−1(·) stacks the R2p-coefficient vector back into a R × Rp matrix,
Q =
©­­­­­«




γR · · · γR2p
ª®®®®®¬
,
where γ1, ..., γR2p are given by
γR2p = τR2pλ1,R2p,




















) = IG(ak, bk), k = 1, ..., R2p, where IG denotes the Inverse-Gaussian distribution




















Note that the conditional distribution of 2τ2k does not have a closed form, but Park and
Casella (2008) showed that g(2 1
τ2
k






) and then transform back to obtain 2τ2k .
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A.3 Error covariance matrices
The Wishart distributions used in the simulation study have 10 degrees of freedom and
symmetric Toeplitz scale matrices of the form:
©­­­­­­­­«
ρ ρ2 · · · ρ5





ρ5 ρ4 · · · ρ
ª®®®®®®®®¬
,
where ρ = 0.3 and 0.1 for cases 4a and 4b, respectively, and 0.2 for all other cases. The block

















Analyses of patient-level observational healthcare databases underpin much of the current
evidence base for healthcare practice. Administrative claims, electronic health record (EHR),
and patient diary databases in particular have seen increased use in the past decade owing
to greater availability at lower costs and technological advances that made computational
processing on large-scale data more feasible (Madigan et al. 2014). Because the data reflect
healthcare activity within a real-world population, they offer the potential to complement
clinical trial results. Administrative claims databases have been the most actively used obser-
vational healthcare data source. These databases typically capture data elements used within
the reimbursement process, as providers of healthcare services (e.g., physicians, pharmacies,
hospitals, and laboratories) must submit encounter information to enable payment for their
services (Hennessy 2006).
Neither administrative claims nor EHRs represent the ideal information required to gener-
ate reliable evidence. For example, diagnoses recorded on medical claims are used to support
justification for the payment for a given visit or procedure; a given diagnosis could represent
the condition that the procedurewas used to rule out or could be an administrative artifact (e.g.,
the code used by a medical coder to maximize the reimbursement amount). Some diagnosis
codes have been studied through source record verification and have demonstrated adequate
performance characteristics (see, for example, Donahue et al. 1997, Hennessy et al. 2010),
whereas other conditions and systems provide less certainty (see, for example, Strom 2001,
Harrold et al. 2007, Lewis et al. 2007). Limitations exist in EHR systems as well, in which,
apart from concerns about incomplete capture, data may be artificially manipulated to serve
clinical care (e.g., an incorrect diagnosis recorded to justify a desired medical procedure).
Patient diary databases capture fewer variables and smaller numbers of patients but offer
significant advantages. In particular, diaries can capture longitudinal data about activities
of daily living, mood, and personal habits and not just when a patient is seeking healthcare.
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Patient diaries support significant research activities in chronic disease management (Zettl
et al. 2016, Nagai et al. 2016, Coolbrandt et al. 2017). Electronic patient diaries capture data
via aweb interface or a phone or tablet and represent themost commonmodality. Participating
patients make diary entries either daily or at multiple times per day, or at set intervals.
Major use cases for observational healthcare databases include inferences about the causal
effects of healthcare interventions (typically via cohort, case-control, or self-controlled case
series designs), healthcare characterization (see, for example, Hripcsak et al. 2016), and
patient-level predictive modeling (PLPM), the primary focus of this paper. PLPM lies right
at the core of healthcare practice and so-called precision medicine. At least implicitly, every
healthcare intervention decision involves a patient-level prediction.
Many researchers have considered the problem of developing predictive models from
patient-level data (see, for example, Kansagara et al. 2011, Stiglic et al. 2015). In the vast
majority of cases, researchers generated a set of candidate covariates thought to be related to
the outcome of interest and employed traditional statistical or machine learning algorithms
to predict the outcome using these covariates. He et al. (2014), for example, predict hospital
readmissions using logistic regression with a modified forward variable selection algorithm
to choose features from the set of all indicator variables for any past occurrence of a medical
concept with a diagnostic code. None of He et al.’s many features, however, conveys any
information about time. Other recent similar approaches include Sanchez-Morillo et al.
(2016), Weng et al. (2017), and Ye et al. (2017).
Some authors have attempted to incorporate explicit temporal information into patient-
level predictive models. In the context of stroke prediction, Shahn et al. (2015) proposed
a “relational random forests” (RRF) that capture “motifs” in the medical history that are
predictive of specific future events. Motifs capture healthcare episodes such as “received
drug X or diagnosis Y then suffered condition Z within T days.” In their target application,
RRF showed modest benefits in predictive performance by reducing predictive errors in the
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test set. Wang et al. (2012) consider a patient’s health history as the superposition and
concatenation of multiple pattern matrices. Each pattern matrix specifies a rigid temporal
relationship among health events that repeats over time. They employ a matrix factorization
algorithm to learn the pattern matrices, which can then be used to construct features for
predictive models. Brzan et al. (2017) show that incorporation of historical patient data
improves predictive performance for hospital readmission prediction.
In this paper, we approach PLPM as a multivariate time series modeling problem and
consider a temporal generative model for the medical record. We adopt a Bayesian approach
and consider an application to patient diary data in the context of drug and alcohol treatment.
We explore the predictive performance of this model. Since the model offers advantages
in terms of interpretability as compared with alternatives such as random forests and deep
learning, we explore insights derived from the model. We apply our model to two patient
diary datasets: the first one includes substance use craving, negative affect, and tobacco use
(Zheng et al. 2013), and the second one includes functional somatic symptoms (FFS) and
psychological discomforts (van Gils et al. 2014).
2.2 Vector autoregressive models for patient diary data
Vector autoregressive (VAR)models represent amainstay ofmultivariate time analysis (Lütke-
pohl 2005). Previous applications of VAR models to patient diary data include Zheng et al.
(2013) and van Gils et al. (2014). However, these studies fit separate models for each in-
dividual patient. Here we take a Bayesian approach and simultaneously model all patients
using a hierarchical model. Bayesian VAR models have been widely applied in various fields
of study such as economics (Litterman 2010, Koop and Korobilis 2010, Karlsson 2015) and
neuroimaging (Gorrostieta et al. 2013). Here we adopt a flexible Elastic-net prior to induce
sparsity in the estimation of the coefficients to aid interpretability (Gefang 2014). The hier-
archical structure for the subject-level coefficients enables simultaneous inference about both
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the population-level and the subject-level coefficients and, in our target application, improves
predictive performance. Our approach also enables estimation of between-subject heterogene-
ity by contrast with ad-hoc approaches such as the clustering analysis on the subject-specific
VAR coefficient estimates deployed by Zheng et al. (2013).
2.2.1 Sparse hierarchical VAR model
Let N denote the number of patients. We assume that each patient records diarymeasurements
atTn time points, n = 1, . . . , N on R variables. Inwhat followswe assume dailymeasurements.
Let ynt = (ynt1, ..., yntR)T be a column vector representing the R measurements at time t,





Ani yn,t−i + nt, t = p + 1, ...,Tn, (2.1)
where Ani, i = 1, ..., p is a R × R coefficient matrix representing the lag-i association, and
nt is the errors, assumed to follow i.i.d. multivariate normal distribution with mean 0 and














is the response variable and ⊗ is the Kronecker product,
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wn = vec([An1, ..., Anp]) (2.5)







∼ MVN(0, ITn−p ⊗ Ω−1) (2.6)
is the stacked error term, and Ik represents a k × k identity matrix.
Here we assume that the precision matrix Ω is the same for all patients but the coefficient
vector wn is unique for patient n. Specifically, we assume that the coefficient vector for the
n-th patient comprises two parts:
wn = w + vn, (2.7)
where w is the population-level coefficient and is the same across all patients, vn is the
patient-level deviation for the n-th patient.
For the population-level coefficient, we adopt the doubly adaptive Elastic-net prior (Gefang
2014). Specifically, we assume that the prior for w follows a multivariate normal distribution
with mean 0 and precision matrix D:





where D is a diagonal matrix and the diagonal elements depend on hyperparameters 2τ2k and
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where λ1,k > 0, k = 1, ..., B2p, and ξ2k, k = 1, ..., R
2p, depend on the error precision matrix Ω
through:
















M = IRp ⊗ Ω−1. (2.12)
We also assume that λ21,k and λ2,k, k = 1, ..., R
2p follow two i.i.d. gamma distributions:
λ21,k ∼ Γ(µ1, ν1) (2.13)
λ2,k ∼ Γ(µ2, ν2) (2.14)
where µ1, ν1 and µ2, ν2 are the corresponding mean and degree of freedom parameters,
assumed to be known. Here, λ1,k and λ2,k represent the L1 and L2 tuning parameters for
the k-th element of w, respectively. It can be shown that the conditional prior for each of
the elements of w given the error precision matrix Ω comprise a normal distribution and
a Laplace distribution. In other words, this prior provides element-wise shrinkage for the
Elastic-net regularization. Note that conditioning on the error precision matrixΩ is important
as it ensures unimodal posterior distribution for each of the elements of w (Park and Casella
2008).
For the patient-level deviations, we apply conjugate i.i.d. multivariate normal priors with
mean 0 and diagonal precision matrix Θv:





for n = 1, ..., N , where the diagonal elements of Θv are
diag(Θv) = (θv1, ..., θv,R2p), (2.16)
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forwhichwe apply the gammahyperpriors on each of the diagonal elements θvk, k = 1, ..., R2p,
i.i.d.:
θvk ∼ Γ(k, s), (2.17)
where k and s are the known mean and degree of freedom parameters (see Gefang (2014) for
parameterization of the gamma distribution). We assume that the patient-level coefficients
are independent of the population-level coefficients given the hyperparameters.
Finally, we use a conjugate Wishart distribution for the error precision matrix Ω:
Ω ∼Wishart(K, ν), (2.18)
where K is the R × R scale matrix and ν is the degree of freedom parameter, both assumed to
be known.
2.2.2 Posterior inference
WeuseMarkovChainMonteCarlo (MCMC) to generate draws from the posterior distribution,
specifically, a Gibbs sampler with parameter expansion (Gelman et al. 2014). A common
computational challenge of Gibbs sampling for hierarchical regression models is that the
sampler can be very slow when there is high dependence between the coefficients and their
variance parameters. For our model, there is strong dependence between vn and its precision
parameters Θv: when the current draw of Θv is large, the next draw of vn will be small,
which in turn makes the next draw of Θv even larger, and so on, so the sampler can take an
impractically long time to explore the entire parameter space.
Using parameter-expansion allows us to reduce inter-parameter correlations and speeds
convergence. Specifically, we add an element-wise multiplicative factor α to vn (i.e., multiply
αk to vnk, k = 1, ..., R2p) and draw α from a multivariate normal distribution just like the
other parameters:
α ∼ MVN(0, aIR2p), (2.19)
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where a is a known constant. In this case, when the current draw of Θv is large, the next
draw of vn will be small, but the next draw of α will be large, which results in the next draw
of vn in a normal range. Thus, the expanded parameterization allows the Gibbs sampler to
move in more directions and avoid getting stuck. These new parameters have no meaning.
However, we are not interested in either α or vn. Rather, the subject-level parameters in this
new parameterization become
v∗n = α ∗ vn, (2.20)
and the true precision of these coefficients become
θ∗vk = α
−2
k θvk, k = 1, ..., R
2p. (2.21)
After obtaining the posterior distributions, we use the posterior modes as the point es-
timates for the parameters in the model. Using posterior modes as point estimates induces
sparsity, and is equivalent to the estimates given by the penalized likelihood methods such as
Lasso (Genkin et al. 2007, Park and Casella 2008)). Here we use the values with the highest
empirical density as the modes of the posterior distribution. This is a crude approach to find
the posterior modes but is computationally efficient for problems with many parameters.
Finally, we use AIC as a criterion to select the optimal order of the VAR model.
2.3 Application 1: predicting substance use craving,
negative affect, and tobacco use among young adults in
recovery
College and university students experience high rates of substance abuse disorders, with
22.9% meeting the diagnostic criteria versus 8.5% of the general population (National Center
on Addiction and Substance Abuse at Columbia University [CASA], 2007). Recognition
of this problem has led at least 20 colleges and universities to develop collegiate recovery
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communities or CRC (Smock et al. 2011) that provide comprehensive recovery support
services and one of these communities provided the diary data for the Zheng et al. (2013)
study. Zheng et al. (2013) examined day-to-day associations among substance use cravings,
negative affect, and tobacco use among 30 college students in 12-step recovery from drug and
alcohol addictions. The intraindividual variability of relevant psychological states combined
with the “one day at a time” nature of sustained abstinence warrant a day-to-day investigation
of substance use recovery. The authors fit first-order vector autoregression models to each
individual predicting daily levels of substance use cravings, negative affect, and tobacco use.
Extensive research has established the relevance of craving as a key criterion in recovery
research (e.g., Stalcup et al. 2006). In turn, negative affect is believed to be a predictor of
craving, and tobacco use is both an important correlate of substance use and craving and a
serious public health risk in its own right. Whether tobacco has any beneficial effects for
persons in recovery remains an open question.
Zheng et al. (2013) present a series of conclusions finding overall that the study revealed
“substantial person-level heterogeneity in the day-to-day processes that challenge continued
abstinence within a college recovery community, providing a picture of accumulated daily
recovery risk that could threaten abstinence over both the short and long term.”
2.3.1 Data and the preprocessing
As in Zheng et al. (2013), the data consist of 55 adult addict patients from CRC at a South-
western university with a total number of 1,222 diary reports (Celeveland and Harris 2010).
In this study, we included 25 patients from the full sample, excluding 12 of the 55 who are
non-smokers, 4 whose diary records exhibit no day-to-day variance, and 14 who have 3 or
more missing daily records. Note that our inclusion criteria differ from those in Zheng et al.
(2013), leading to the inclusion of a few more patients than were included in their study. All
participants were fully anonymized before accessing to the data. All are non-Hispanic White.
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All had received professional alcohol/drug dependency treatment. All had received inpatient
care, most for 3 months or more. All considered themselves 12-step group members and
reported that they read 12-step literature and applied the steps to their lives on a daily basis.
Participants provided an average of 25.56 days’ worth of data each (ranging from 10 to 33
days), with the average participant missing 0.8 days (ranging from 0 to 2 days).
The following three variables are considered in our application. They are the same as in
Zheng et al. (2013) (see Zheng et al. (2013) for descriptive statistics for the three variables
and the number of observations for each participant).
Tobacco use. Daily tobacco usewasmeasuredwith one item asking, “Howmany cigarettes
did you smoke today?” Responses ranged from 0 (no cigarettes), 1 (1 or 2), 2 (2 to 5), 3 (5 to
10), 4 (half pack) to 5 (full pack plus).
Negative affect. Zheng et al. (2013) used the 10-item negative affect scale from the Positive
and Negative Affect Scale to assess daily negative affect. Emotions included “Stressed,”
“Upset,” “Scared,” “Hostile,” and “Irritable.” Responses ranged from 1 (very slightly or not
at all) to 5 (very much).
Substance use craving. Daily substance use craving was measured with seven items modi-
fied from the Desires for Alcohol Scale and the Alcohol Urges Questionnaire to accommodate
daily assessment and polydrug use. A sample item reads, “For a moment today I missed the
feeling of drinking or drugging.” Responses were 1 (strongly disagree) to 5 (strongly agree).
Our pre-processing step includes missing data imputation using the mean of the non-
missing consecutive days, log-transformation of all three variables to improve normality,
standardization to mean 0 and variance 1 and removal of linear trend for each time series for
each patient.
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2.3.2 Hyperpriors used in the model
We used weakly informative priors that are conjugate but almost flat on the parameter space
in the spirit of Gefang (2014). In particular, we assume λ21,k and λ2,k, k = 1, ..., R
2p, follow
the Γ(1, 0.001) and the Γ(1, 0.01) distributions, respectively, the diagonal elements of Θv
are assumed to follow Γ(1, 0.01), and the precision matrix of the error terms Ω is assumed
to follow Wishart((R − 1)IR, 1). We assume the multiplicative variables α follow a diffuse
normal distribution: MVN(0, 100IR2p).
2.3.3 Criterion to assess model performance
We use prediction accuracy as a criterion to assess the performance of the proposed Bayesian
VAR model to compare with the patient-specific VAR models used in Zheng et al. (2013). In
particular, all but the last daily record of each individual patient are used to train the model
and the last daily record is used as a test set.
We use the posterior predictive distributions to predict the test data (the procedure is
described in detail in Karlsson 2015). Specifically, each individual sample of the 1-step
ahead forecast for subject n, n = 1, ..., N , is generated by the posterior samples of the VAR




Aˆni yn,Tn+1−i + ˆn,Tn+1, (2.22)
where ˆn,Tn+1 is drawn from a multivariate normal distribution with mean 0 and precision
matrix equal to one posterior sample of Ω:
ˆn,Tn+1 ∼ MVN(0, Ωˆ−1). (2.23)
Posterior means and the 2.5-th and 97.5-th posterior percentiles of these posterior predictive
samples are used as point and interval estimates of the prediction. Note that using posterior
modes for parameter estimation enforces sparsity and interpretabilitywhile the use of posterior
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means minimizes mean squared error (MSE) for forecasts (Karlsson 2015). For the patient-
specific VAR model that was utilized in Zheng et al. (2013), patient-specific maximum-
likelihood estimates (MLE) are used to predict the test observations for each individual
patient. Estimated MSE and coverage probability of the 95% predictive intervals (estimated
by the percentage of the intervals containing the true values of the test data points) are used
to assess prediction accuracy on the test set for both models.
2.3.4 Results
2.3.4.1 Posterior sampling and order selection
We fit two hierarchical VAR models with order one and two, respectively. The posterior
sampling procedure was implemented in R. Specifically, we ran 10,000 iterations across
4 chains and used the first half of the iterations as warmup iterations. The second half
was thinned by every 20 iterations to break the autocorrelation in the posterior samples,
ending up with 250 samples per chain for posterior inference. All 4 chains mixed well and
converged to similar stationary distributions for all parameters according to the criterion of
Rˆ < 1.1 (Gelman et al. 2014). No serial correlations are found in the chains. The number of
parameters for this example is about 300 for VAR(1) and 600 for VAR(2).
For this particular example, the model with order one resulted in a smaller AIC (3027.951)
and is favored. Since the second ordermodel underperformed thefirst ordermodel (AIC=3466.319),
we did not pursue higher orders. We note that Zheng et al. (2013) fit VAR(1) models to each
individual patient. In fact, since there is one patient who has only 9 days of daily records in
the training data, maximum likelihood estimation for models of higher order than one results
in singularity problems, requiring a Bayesian and/or regularized approach.
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2.3.4.2 Population-level coefficients
Figure 2.1 shows the posterior modes of the population-level coefficients. The three variables
of interest are shown in the circles, where “T" represents tobacco use, “N" represents negative
affect and “C" represents substance use craving. The arrows represent the lag-1 associations
between the variables. In particular, the red arrows show positive associations and the
blue arrow shows the negative association. The solid arrows represent the “significant”
associations. Specifically, the pink arrow indicates that a 90% interval does not contain 0.
The transparent arrows show the associations that are not significant. One can see from Figure
2.1 that tobacco use in the previous day has the strongest positive effect on the tobacco use
in the current day, followed by negative affect in the previous day on the negative affect and
substance use craving in the current day. Moreover, craving in the previous day has a small
negative effect on itself in the current day.
2.3.4.3 Patient-level parameters
Figure 2.2 shows the posterior modes of the patient-level deviations. In these plots, the solid
red arrow indicates that a 95% posterior interval does not contain 0. We see that several
lag-1 associations between the three variables of interest are zero for most patients, including
negative affect and craving in the previous day on themselves in the current day, as well as
negative affect in previous days on tobacco use and craving in the current day. For the non
zero associations, tobacco use in the previous day has an effect on tobacco use in the current
day for all patients. Craving in the previous day also has an effect on tobacco use in the
current day for almost all patients. These associations vary across different patients in terms
of both sign and magnitude.
Figure 2.3 shows the posterior modes of the standard deviation of the patient-level coeffi-
cients (i.e., the square root of the inverse of the diagonal elements of Θv). The solid arrows
show the associations with large patient-level heterogeneity: the largest one is the effect of
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Figure 2.1: Posterior modes of the population-level coefficients. T=tobacco use, N=negative affect,
C=cravings. Red=positive, blue=negative. Solid lines=significant coefficients (red: α = 0.05; pink:
α = 0.1), transparent lines=non-significant coefficients.
previous tobacco use on current tobacco use, followed by previous craving on current tobacco
use and negative affect. This is consistent with the findings in Figure 2.2.
2.3.4.4 Prediction accuracy
Table 2.1 shows the estimated MSE’s of the proposed Bayesian hierarchical model compared
with the conventional patient-specific VAR model. We see that the hierarchical model
improved the accuracy of the prediction. The overall mean square error averaged over all
three variables is reduced by 25%. For the individual variables, predictive accuracy is better
using the hierarchical model relatively to the patient-specific VAR model with the mean
square errors reduced by 17% for tobacco use, 3% for negative affect and more than 37%
for craving, respectively. This shows the advantage in terms of predictive accuracy of the
hierarchical model which pools the information across patients.
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Figure 2.2: Posterior modes of the patient-level deviations. Each panel represents one patient.
T=tobacco use, N=negative affect, C=cravings. Red=positive, blue=negative. Solid lines=significant
coefficients (red: α = 0.05; pink: α = 0.1), transparent lines=non-significant coefficients.
Figure 2.4 shows the prediction of the test data along with the 95% intervals for all subjects
using the proposed Bayesian model and the maximum-likelihood estimates. The circles
represent predictions using the patient-specific VAR models and the triangles represent the
Bayesian estimates. The lines going through the circles and the triangles represent the 95%
intervals. Red stars show the true test observations. The number of time points in the training
data for each subject are shown as well. We see that for the patients who have moderately large
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Figure 2.3: Posterior modes of the standard deviation of the patient-level deviations. T=tobacco
use, N=negative affect, C=cravings. Red=positive, blue=negative. The first three largest standard
deviations are shown in solid arrows.
Table 2.1: Estimated MSE of the hierarchical VAR model and the patient-specific VAR model. %
reduction in MSE given by the Bayesian model relative to the patient-specific VAR models are shown.
T=tobacco use, N=negative affect, C=craving.
Model Overall MSE MSE by VariableT N C
Hierarchical VAR .722 .459 .704 1.002
Patient-specific VAR .964 .554 .731 1.608
% Reduction 25.1% 17.1% 3.5% 37.7%
number of observations (above 20 time points), the point estimates are quite similar for both
methods. However, for the subject with a small number of observations (subject 14 has only
9 training observations), Bayesian prediction is remarkably better than the patient-specific
VAR model for cravings.
The estimated coverage probabilities of 95% predictive intervals are, respectively, 97%
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Figure 2.4: Posterior means and the 95% intervals for the 1-step ahead prediction. T=tobacco use,
N=negative affect, C=craving. The circles represent the predictions given by the subject-specific
MLE’s and the triangles represent the Bayesian estimates. The lines show the 95% intervals. Red stars
are the true future observations. Number of observations (Tn, n = 1, . . . , 25) for each subject is shown.
and 93% and for the Bayesian model and patient-specific VARmodels. For a nominal level of
95%, we would expect about 95% of the predictive intervals to contain the true values. Both
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methods are close to the nominal level. However, 68% of the Bayesian intervals are narrower
than their patient-specific counterparts. This shows that the Bayesian method can not only
provide more accurate point estimates but also a more satisfactory range estimate as well.
2.4 Application 2: predicting functional somatic
symptoms (FSS) and psychological discomforts
Approximately 20% to 50% of the physical symptoms presented in primary care and hospital
settings cannot be fully explained by organic pathology (Peveler et al. 1997, Fink et al.
1999, de Waal et al. 2004). These symptoms are commonly referred to as functional somatic
symptoms (FSS). Previous studies in epidemiology have suggested greater stress (Greene et al.
1985, Robinson et al. 1988, Hatcher and House 2003) and other psychological discomforts
(de Benedittis and Lorenzetti 1992, Hesketh et al. 2010) in people who suffer from FSS’s
than those who do not. Utilizing patient diary databases, a few studies have shown cross-
relationship between stress and FSS’s in both directions within subjects over time (Dancey
et al. 1998, Connelly and Bickel 2011).
To investigate bidirectional relationship and temporal precedence between stress and FSS’s
within individual patients, van Gils et al. (2014) adopted a VAR modeling framework on data
from a diary study with patients who had multiple, persistent FSS’s, including external and
internal body pain and autonomics (Burton et al. 2009). Granger causality models on stress
and a single FSS were performed for each individual patient and each individual FSS. An
increase in one or more FSS’s were found to be significantly predictable by preceding (mostly
first-lag) increase in stress for 30% of the patients, and reverse association in 15% of the
patients. Substantial between-patient heterogeneity in the lagged associations between the
FSS’s and stress was also reported.
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2.4.1 Data and the preprocessing
54 patients (age between 21 and 65 years) with persistent FSS’s and psychological discomforts
were recruited by medical practitioners in a 12-week study between January 2014 and Febru-
ary 2016. Standard handheld personal digital assistant (PDA) computers with the PalmTM
operating system are used to record daily diary on 14 FSS’s (muscle pain, joint pain, back
pain, headache, abdominal pain, pelvic pain, bowel symptoms, dyspepsia, nausea, tight throat,
chest pain, weakness, numbness and palpitations) and 5 psychological discomforts (stress, fa-
tigue, anxiety, depression and illness concern). Patients entered 1-3 records on each day, with
each data entry consisted of 3 most severe symptoms out of the 14 FSS’s all 5 psychological
discomfort measures (all patients entered the same 3 symptoms throughout the entire study).
FSS’s. Diary questions with respect to FSS’s were phrased as follows: “How much have
you been bothered by symptom X? Please mark a point on the line between severe symptom
X and no symptom X at all." (1-150).
Psychological discomforts. The level of stress and other psychological discomforts were
assessed using the following question: “How stressful (fatigue, anxiety-arousing, depressing,
illness-concerning) are people and things around you? Please mark a point on the line be-
tween very stressful (fatigue, anxious, depressed, illness-concerned) and not stressful (fatigue,
anxious, depressed, illness-concerned) at all." (1-150).
Since only 3 out of the 14 FSS’s were recorded at each diary entry for each patient,
most of the FSS’s were recorded by a small number of patients. We therefore use subsets of
the data on 4 of the FSS’s (headache, joint pain, bowel symptoms, muscle pain) that were
recorded by the greatest number of patients (N=12, 12, 10, 15, respectively). For example,
12 patients recorded the symptom headache during the study and are thus included in the first
subset. For each of the 4 FSS’s (i.e., the 4 subsets), we extend the previous work in van Gils
et al. (2014), where the relationship between one FSS and stress was considered, and fit the
proposed Bayesian VARmodel on the FSS and all 5 psychological discomfort variables. This
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results in 4 models, each of which considers 6 variables. The average (range) length of diary
records for the 4 FSS’s are, respectively, 90 (64-126), 89 (64-131), 86 (64-109), 90 (83-126)
days, with average (range) number of missing daily records 9 (0-37), 9.5 (0-47), 6 (0-24), 4.4
(0-37), respectively.
The preprocessing of the data included: 1) averaging of the variables for each day and
each patient to ensure one observation per day per patient, if there are more than one records
entered on the same day for the same patient ; 2) missing value imputation using moving
average imputation embedded in R package ‘impureTS’ (https://cran.r-project.org/
web/packages/imputeTS/index.html); 3) log-transformation of each of the 6 variables
to improve normality; 4) standardization to mean 0 and variance 1 and removal of linear trend
for each time series for each patient.
We use the same posterior sampling strategy and hyperpriors in Section 2.3 for this
application. We use the last 10 observations of each patient as test data and the remainder
training data. 1-step ahead forecasting was performed using the same technique in Section
2.3 and h-step ahead forecasting, h = 2, . . . , 10, was performed using the recursive algorithm
described in Karlsson (2015). Posterior modes of the parameters are used for statistical
inference. Assessment of prediction accuracy (i.e., MSE of the posterior means and coverage
probabilities of 95% predictive intervals) and model order selection (i.e., AIC) are the same
as Section 2.3.
2.4.2 Results
2.4.2.1 Posterior sampling and order selection
For each of the 4 models, we ran 10,000 iterations across 4 chains and used the second half
of the iterations (thinned by every 20 iterations, yielding 250 samples per chain) for posterior
inference. All chains mixed well and converged to the stationary distribution. No serial
correlations are found in the chains. VAR(1) models outperformed VAR(2) models with
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smaller values of AIC across all 4 models (the VAR(1) models for the 4 FSS’s have AIC
values 5956.6, 6172.1, 4722.8, 7416.8, respectively, and the VAR(2) models 7069.7, 7215.8,
5720.3, 8674.5). We therefore favor VAR(1) models in this application.
2.4.2.2 Population-level coefficients
Figure 2.5 displays the posterior modes of the population-level coefficients for the 4 models
(panel (a)-(d) represent FSS=headache, joint pain, bowel symptom and muscle pain, respec-
tively). The coefficient at the r-th row and the c-th column in each panel represents the effect
of the c-th variable in the previous day on the r-th variable in the current day. Significant
coefficients (at level α = 0.1) are in bold font. Purple box on each panel represents the effect
of the psychological discomforts in the previous day on the FSS in the current day; blue box
represents the reverse effect of FSS in the previous day on the psychological discomforts in
the current day.
Inspection of Figure 2.5 indicates that most FSS’s and psychological discomfort variables
have positive effects on themselves. Most of the cross-relationships between FSS’s and psy-
chological discomforts are positive and the magnitudes are smaller than the autocorrelations
of the variables. The strongest cross-associations between FSS’s and psychological discom-
forts include the effect of stress in the previous day on bowel symptoms in the current day, the
effect of anxiety in the previous day on muscle pain in the current day and the effect of muscle
pain in the previous day on illness-concern in the current day. Moreover, there are significant
associations between the psychological discomfort variables, including the effect of anxiety
on depression for patients who reported headache, fatigue on depression for patients who
reported joint pain, stress on anxiety for patients who reported bowel symptoms, and anxiety
on fatigue for patients who reported muscle pain.
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Figure 2.5: Posterior modes of the population-level coefficients for the 4 FSS’s. Panel (a)-(d) display
FSS=headache, joint pain, bowel symptoms and muscle pain, respectively. The coefficient at the r-th
row and the c-th column in each panel represents the effect of the c-th variable in the previous day on the
r-th variable in the current day. Significant coefficients (at level α = 0.1) are in bold font. Purple box on
each panel represents the effect of the psychological discomforts in the previous day on the FSS in the
current day; blue box represents the effect of FSS in the previous day on the psychological discomforts
in the current day. Head=headache, Join=joint pain, Bowe=bowel symptoms, Musc=muscle pain,
Fati=fatigue, Stre=stress, Depr=depression, Anx=anxiety, Conc=illness-concern. Color scale ranges
from -0.5 to 0.5
2.4.2.3 Between-patient heterogeneity
Figure 2.6 displays the posterior modes of the standard deviations of the patient-level devi-
ations for the 4 models (Panel (a)-(d) represent FSS=headache, joint pain, bowel symptom
and muscle pain, respectively). The highest between-patient heterogeneity lies in the auto-
correlation of fatigue. This is consistent across all of the 4 FSS’s. For cross-relationships
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between the FSS’s and the psychological discomforts, highest between-patient heterogeneity
was present in the effect of headache on illness-concern and depression, the effect of anxiety
on headache, the effect of illness-concern and depression on joint pain, and the effect of stress
on muscle pain. This is consistent with the previous studies which have found substantial
between-subject heterogeneity in the association between stress and FSS’s (Burton et al.
2009).
2.4.2.4 Prediction accuracy
Table 2.2 displays the performance of predicting the10 test data points using the Bayesian
VAR model and the conventional patient-specific VAR models for the 4 FSS’s. Figure 2.7
displays the h-step forecasting, h = 1, . . . , 10, on headache for all patients who reported this
FSS. The black and blue lines display, respectively, the prediction given by the Bayesianmodel
and the patient-specific VAR models. Solid lines represent the point estimates and dashed
lines the predictive intervals given by the two methods. Red dots show the true values of the
test data points. We can see that both methods performed similarly, with Bayesian model
slightly better than the patient-specific VAR models across all 4 FSS’s. This is probably due
to the fact that the number of observations (Tn, n = 1, . . . , N) for each patient in the training
data is much greater than that in Section 2.3, so the Bayesian model utilized much more
information contained in the data than in the prior distributions, leading to similar behavior to
the maximum-likelihood approach. Nevertheless, the Bayesian model still outperformed the
patient-specificmodels in point estimates due to the pooling among subjects. For the estimated
coverage probability, both model tend to slightly overcover (with the Bayesian model slightly
more overcovered), but the Bayesian model provides shorter predictive intervals due to the
shrinkage imposed by the priors.
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Figure 2.6: Posterior modes of the standard deviations of the patient-level deviations for the 4 FSS’s.
Panel (a)-(d) display FSS=headache, joint pain, bowel symptoms and muscle pain, respectively. The
number at the r-th row and the c-th column in each panel represents the standard deviation of the
effect of the c-th variable in the previous day on the r-th variable in the current day. Purple box
on each panel represents between-patient heterogeneity in the effect of the psychological discom-
forts in the previous day on the FSS in the current day; blue box represents the between-patient
heterogeneity in the effect of FSS in the previous day on the psychological discomforts in the cur-
rent day. Head=headache, Join=joint pain, Bowe=bowel symptoms, Musc=muscle pain, Fati=fatigue,
Stre=stress, Depr=depression, Anx=anxiety, Conc=illness-concern. Color scale ranges from 0 to 0.3.
2.5 Discussion
In summary, we proposed a novel Bayesian hierarchical VAR model for PLPM. Our model
simultaneously estimates population-level and patient-level coefficients, as well as estimating
between-patient heterogeneity. It provides sparse estimates leading to better interpretability
and visualization, as well as higher predictive accuracy.
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Table 2.2: Prediction accuracy of the Bayesian VAR model and patient-specific VAR models. Esti-
mated MSE’s and coverage probabilities are shown for each single FSS. % reduction in MSE and %
shorter predictive intervals given by the Bayesian model relative to the patient-specific VAR models
are shown.
Headache Joint Pain Bowel Symptoms Muscle Pain
MSE
Bayesian VAR model 0.743 0.694 0.568 0.698
Subject-specific VAR model 0.744 0.698 0.584 0.704
% Reduction 0.18% 0.58% 2.75% 0.90%
Coverage probability
Bayesian VAR model 0.965 0.964 0.97 0.966
Subject-specific VAR model 0.954 0.961 0.968 0.958
% Shorter interval 64% 65% 62% 68%
Application of our model to previous diary studies showed improvement in patient-level
prediction in terms of both point and range estimates. The advantage of the partial pooling
among subjects in the Bayesian model is more substantial for datasets with a small number of
observations for certain patients. When the number of observed time points are sufficiently
large for all patients in the data, the Bayesian model behaved similarly to the conventional
patient-specificVARmodels. Nevertheless, theBayesianmodel still outperformed the patient-
specific models by providing more information about the population-level coefficients and the
between-subject heterogeneity as well as improving prediction accuracy for the future data.
In the examples, we used weakly informative hyperpriors which are conjugate but almost
flat on the parameter space. This provides convenient derivation of the conditionals used in
the Gibbs sampler while enforcing little prior information. We also tried different values of
the hyperparameters but these yielded very similar results.
Further, in the examples, we used posterior modes as parameter estimates for better
interprebility and visualization. However, we also tried posterior median. Due to the fact that
the posterior distributions are symmetric and unimodal for most of the parameters, the results
were very similar in terms of both parameter estimation and future data prediction, although
sparsity in the parameter estimation then no longer exists.
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Figure 2.7: Posterior means and 95% intervals for predicting headache for all patients who reported
this FSS using the Bayesian VAR model and patient-specific VAR models. Each panel represents
one patient (the index shows the h-step forecasting, h = 1, . . . , 10). The black and blue lines display,
respectively, the prediction given by the Bayesian model and the patient-specific VAR models. Solid
lines represent the point estimates and dashed line the predictive intervals given by the two methods.
Red dots show the true values of the test data points. Number of observations (T) for each patient is
displayed in each panel.
Finally, in both applications, the prediction of future data is near 0, indicating that nei-
ther models suitably describes these data. One possible remedy, to be explored in future
work, is the inclusion of covariates such as demographic variables and/or time information
such as weekdays versus weekends, which might lead to more precise predictions of future
observations.
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Appendix B
Appendix to Chapter 2
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B.1 Full conditional distributions
To draw from posterior distribution using Gibbs sampler, one draws each parameter from its
conditional distribution given all other parameters at their current values. Let g(·) denote
conditional distribution of one parameter given others. We now give the full conditionals of
all parameters.
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where wˆn is the MLE of the VAR coefficients for the n-th patient;































where Diag(·) represents assigning the R2p vector on a diagonal matrix;











































where vnk is the k-th element of vn;
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, k = 1, ..., R2p, where
νλ21,k
= ν1 + 2,
µλ21,k
=











, k = 1, ..., B2p, where







where wk is the k-th element of w;













Sn = (Yn −WnHn)(Yn −WnHn)T
is the residual matrix of the n-th patient,
Yn =
(
yn,p+1 · · · yn,Tn
)
is a R × (Tn − p) matrix,
Wn = vec−1 (w + α ∗ vn) ,
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Note that the conditional distribution of 2τ2k is complicated, but Park and Casella (2008)
have shown that g( 12τ2
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) and then transform back to get 2τ2k .
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Chapter 3




Electrical stimulation mapping (ESM) has become a widely used technique to determine
localization of brain areas responsible for certain neurophysiological functions, called func-
tional localization, in an individual patient’s cortex. Localization of cortex sites related to
language commonly utilizes mapping during an object naming task (Penfield and Roberts
1959, Ojemann et al. 1989). Sites where stimulation interferes with naming are often quite
focal in regions of frontal and temporal cortex, but with substantial variability between pa-
tients in their exact location. It has been shown that those sites are crucial for language, in that
a resection that encroaches on them is likely to be associated with a postoperative language
deficit, while one that does not is unlikely to have a deficit (Ojemann 1983b, Haglund et al.
1994). The extent to which these crucial sites remain in the same location over time in an in-
dividual adult patient is controversial. Individual cases have been described that seem to show
evidence for substantial variability (Duffau et al. 2002, Seek et al. 2006, Duffau 2011), and
for apparent stability (Ojemann 1983a, Ojemann et al. 2003, Robles et al. 2008, Serafini et al.
2013). In general, studies in patients with intrinsic gliomas have more often shown changes
interpreted as evidence of variability, those in patients with epilepsy, changes interpreted as
evidence for stability, but there are exceptions in both disease groups. More importantly,
previous studies all utilized qualitative approaches (such as simply comparing sites identified
during repeat mappings graphically) and none of them has examined the variability in these
locations systematically via quantitative measures.
Mapping language sites quantitatively over time presents two particular challenges. First,
within a given patient, different numbers of sites might be mapped across repeat mappings.
Figure 3.1(a) shows an example of a patient that illustrates this issue. For this patient, five
sites are observed during the first mapping but only one site is observed during the second
mapping. A second challenge concerns the matching of the sites across mappings. Consider
the patient represented in Figure 3.1(b). While we expect sites to exhibit some spatial stability
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Figure 3.1: An example to illustrate the challenges inmodeling repeat Electrical SimulationMappings.
Panel (a): unequal number of sites mapped during the two mappings; Panel (b): matching between
the sites.
over time, the site from the second mapping in the lower left quadrant could “belong” to any
of the four sites from the first mapping.
We propose a Bayesian model to address these two challenges and provide assessment of
variability in language localization quantitatively. Specifically, we assume that the discrepancy
in numbers of sites mapped during the 2 mappings is due to missing observations. Take the
example in Figure 3.1(a), this means that we assume that the five language sites do exist and
treat the four absent locations in the second mapping as missing data. We use augmented
MarkovChainMonte Carlo (MCMC) to impute thesemissing values. Moreover, wemodel the
matching between the sites probabilistically, favoring solutions that respect spatial stability,
but incorporating uncertainty in the matching process. We also assume that language sites
do not “jump” across different regions in the brain (e.g. from temporal lobe to frontal or
parietal lobe), a common assumption in neurophysiology. We adopt a hierarchical model to
analyze the variability in the localization across different individual regions. We apply our
model to a series of patients with medically refractory epilepsy, who had serial mapping of
language with a standardized object naming task over intervals of 1 to more than 20 years,
assessing changes in perisylvian localization in language dominant hemisphere over time.
These findings provide some further insight into what differentiates these crucial areas from
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surrounding cortex, and on the degree of cortical plasticity in the adults.
We proceed as follows. Section 3.2 describe the Bayesian method and the augmented
MCMC procedure to impute missing sites and obtain probabilistically optimal matching
between the sites. Section 3.3 describes the real data analysis using the proposed approach
and provides visualization of the results. Section 3.4 concludes.
3.2 Method
3.2.1 A regional hierarchical model
We propose a Bayesian hierarchical model motivated by the challenges outlined in Section
3.1. Suppose the sites are observed across R regions, where each region is a particular section
in the cortex. Denote by (X sir j,Y sir j)T the xy-coordinates of mapped site j = 1, ..., nsir for
patient i = 1, ..., N at region r = 1, ..., R during mapping s = 1, 2, where nsir is the total
number of sites mapped for patient i at region r during mapping s. We assume that sites
arise from independent bivariate normal distributions given the constant true latent location











where (µXir j, µYir j )T is the mean vector for mapped site j of patient i at region r , and σr > 0 is
the standard deviation for region r , assumed to follow an i.i.d. log-normal distribution with
hyperparameters a and b, b > 0:
σr ∼ Lognormal(a, b2), r = 1, . . . , R. (3.2)
To address the challenges of unequal number of mapped sites during the twomappings and
the matching between the sites, we introduce two sets of augmented variables in the model.
Denote M ir = (Mir1, . . . ,Mirnir )T the matching vector of the sites (observed or missing)
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across the two mappings for patient i at region r , where Mir j = k if the j-th site in the
first mapping matches to the k-th site in the second mapping and nir = max(n1ir, n2ir) is the
maximum number of sites mapped over the two mappings. If a site (X sir j,Y sir j)T is missing, we
denote the corresponding unobserved value by Z ir j = (ZX,ir j, ZY,ir j)T (note that we suppress
the superscript s here because there can be at most one missing value occurring at either
mapping). Table 3.1 shows a synthetic example of mapped sites for a particular patient within
a particular region, where 4 sites are mapped at the first mapping (column 1) and only 2 are
mapped at the second mapping (column 2). Column 3 lists an example matching between the
4 sites.
Table 3.1: A synthetic example of sites mapped for patient i within region r during the 2 mappings.
Column 1: 4 observed sites at the first mapping; Column 2: 2 observed sites and 2 missing sites at the
second mapping; Column 3: an example matching vector between the 4 sites; Column 4: description
of the matching.








T matches Z ir4
(X1ir3,Y1ir3)
T





Z ir4 2 (X1ir4,Y1ir4)
T matches (X2ir2,Y2ir2)
T
We assume non-informative priors for the mean vectors (µXir j, µYir j )T , the matching vector
M ir , the missing value Z ir j and the hyperparameters a and b. Note that in this model,
the variance parameters σr, r = 1, . . . , 4, and the exponentiated hyperparameter ea are the
primary quantities of interest as they quantify the variability in localization of the language
sites within and across the regions mapped during the 2 mappings.
3.2.2 Gibbs sampler with Metropolis-Hasting updates
To sample from the posterior distribution, we implement the Gibbs sampler algorithm with
Metropolis-Hasting updates for each parameter (Gelman et al. 2014). Specifically, for each
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iteration t = 1, . . . ,T , we alternately update the parameters one at a time by proposing new
values from the following jumping distributions:
1. draw σ(t)1 ∼ TN0(σ(t−1)1 , 0.42);
2. draw σ(t)r ∼ TN0(σ(t−1)r , 0.22), r = 2, . . . , 4;
3. draw µ(t)Xir j ∼ U(µ
(t−1)
Xir j
− 4, µ(t−1)Xir j + 4);
4. draw µ(t)Yir j ∼ U(µ
(t−1)
Yir j
− 4, µ(t−1)Yir j + 4);
5. draw Z (t)Xir j ∼ U(Z
(t−1)
Xir j
− 6, Z (t−1)Xir j + 6);
6. draw Z (t)Yir j ∼ U(Z
(t−1)
Yir j
− 6, Z (t−1)Yir j + 6);
7. draw a(t) ∼ U(a(t−1) − 2, a(t−1) + 2);
8. draw b(t) ∼ TN0(b(t−1), 22);
9. draw M (t)ir uniformly from all possible permutations of M ir,
where TN0(·) stands for a truncated normal distribution on (0,∞), U(·) represents the uniform
distribution, and the subscript (t − 1) represents the current value of a particular parameter at
iteration t−1. The jumping sizes of these distributions are chosen such that the acceptance rate
is about 0.2, which is believed to be a decent acceptance rate for high-dimensional problems
(Gelman et al. 2014). We drew 4 chains using 2 million iterations for each chain, with the
first half used as warm-up iterations. We then thinned the remaining 1 million to 200 samples
per chain, ending up with 800 posterior samples altogether. All chains mixed well using the
criteria of Rˆ < 1.1 (Gelman et al. 2014) and have no serial correlation. The entire posterior
sampling procedure is implemented in R.
Notice that within all possible permutations of M ir , some of them are redundant due
to matching observed sites to missing sites. Taking the example in Table 3.1, two possible
permutations are M ir = (3, 4, 1, 2) and M ir = (4, 3, 1, 2). Including both permutations in the
pool of proposing values will create a mixture of the posterior samples for the imputed values
and cause mixing problem of the chains. We therefore treat these two permutations equivalent
and only allow the proposing values for matchings involving missing sites to be in increasing
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order. Using, again, the example in Table 3.1, this means that we only keep the permutation
M ir = (3, 4, 1, 2) in the proposing pool and eliminate M ir = (4, 3, 1, 2) because the first two
values in the former vector (i.e., (3,4)) involve the missing sites and are in increasing order.
3.3 Application
3.3.1 Electrical Stimulation Mapping
We now apply our model to a real dataset to investigate the variability of language sites
over time. The data consist of 22 patients, all of whom have received two resections in the
language dominant hemisphere, 21 in left brain, 1 in right. Mean age at first operation was
27.7 years (range 10-39). The second operation occurred a mean of 8.35 years (range 1-20.25)
after the first. Electrical Stimulation Mappings of language had occurred at both operations,
utilizing a standard measure of object naming task (Ojemann et al. 1989). In the entire
series, a total number of 246 sites common to the areas of mapping in both operations were
mapped, of which 99 sites have positive stimulation interfered with naming and are included
in here. These sites are located across 4 brain regions, including anterior temporal, posterior
temporal, frontal and parietal, with the number of sites mapped within a certain region during
one mapping ranging from 1 to 4. 20 of the patients have at least one site missing during
either of the two mappings. Certain sites mapped during the two mapping are closer to each
other than the other sites. Figure 3.2 shows the mapped sites for two patients during the two
mappings. Yellow and white marks show, respectively, sites mapped at the first and second
mapping; blues circles have radius of 1cm in Panel (a) and 5 and 10cm in Panel (b).
3.3.2 Stability in localization of language sites
Figure 3.3 shows the posterior sampling distributions for the variance parameters σr, r =
1, . . . , 4, and the hyperparameters a and b. Red solid lines and blue dashed lines show,
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Figure 3.2: Sites mapped for two patients at two Electrical Stimulation Mappings. Yellow and white
marks show, respectively, sites mapped at the first and second mapping; blues circles have radius of
1cm in Panel (a) and 5 and 10cm in Panel (b).
respectively, the posterior medians and 95% posterior intervals based on equal-tailed posterior
quantiles. These numbers are also shown in Table 3.2 (Column 2). One can see that, the
posterior medians are around 0.6cm and the 95% posterior intervals have approximately a
range of (0.4,0.9) across all 4 regions. The posterior distribution ofσ1 in the anterior temporal
region is slightly more variable and heavy-tailed than the other three regions. The posterior
median for ea is, again, approximately 0.6cm, and the 95% posterior interval has a range of
(0.3,1.1). This suggests substantial stability in the localization of language sites within each
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Figure 3.3: Posterior sampling distributions for σr, r = 1, . . . , 4, and the hyperparameters a and b (ea
is shown for the hyperparameter a). Red solid lines display posterior medians and blue dashed lines
display the 95% posterior intervals based on equal-tailed posterior quantiles. The range in the panels
is 0-6 for σ1 and 0-2 for σr, r = 2, 3, 4.
cortex region mapped over the entire study period.
Table 3.2: Posterior median and 95% intervals based on equal-tailed quantiles (shown in brackets) for
σr, r = 1, . . . , 4, and the hyperparameters a and b. Column 2: pooled sample; Column 3: long elapse
group; Column 4: short elapse group.
Parameter All patients Long elapse group Short elapse group
σ1 0.59 (0.29,1.22) 0.65 (0.17,5.5) 0.57 (0.27,1.23)
σ2 0.69 (0.57,0.87) 0.72 (0.53,1.03) 0.67 (0.52,0.89)
σ3 0.62 (0.45,0.91) 0.59 (0.27,1.45) 0.63 (0.44,1.03)
σ4 0.53 (0.4,0.69) 0.58 (0.43,0.81) 0.46 (0.29,0.73)
ea 0.61 (0.32,1.12) 0.64 (0.17,2.14) 0.58 (0.21,1.17)
b 0.27 (0.02,1.95) 0.41 (0.03,3.43) 0.35 (0.02,2.43)
Figure 3.4 show, respectively, the posterior sampling distributions for the same parameters
as in Figure 3.3 for patients who have short (< 7 years) and long (> 7 years) elapses between
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Figure 3.4: Posterior sampling distributions for σr, r = 1, . . . , 4 and the hyperparameters a and b
for different elapse groups. Red lines: patients who had long elapse (> 7 years) between the two
mappings; blue lines: patients who had short elapse (< 7 years) between the two mappings; grey line:
pooled sample. Posterior medians for the three groups of patients are shown on top of each panel.
the 2 mappings, represented by blue and red lines, respectively. Each group consists of 11
patients. Grey lines show the posterior distribution for the pooled sample. Posterior medians
for the 3 groups of patients are shown on top of each plot with the corresponding colors. Table
3.2 shows the posterior median and the 95% intervals for the two groups. We can see that the
posterior medians of all three groups are around 0.6cm and the upper bound of 95% intervals
around 2cm, confirming that the localization of languages sites are generally stable over time.
Nevertheless, the long elapse group resulted in higher posterior medians and wider posterior
intervals than the short elapse group for most of the regions. This suggests that over a very
long period of time, the movement in language locations does gradually increase in distance
and spread.
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3.3.3 Visualization of imputed missing sites and matching
Figure 3.5-3.26 visualize the imputed missing sites and the matching between the sites
mapped during the two mappings for each patient. Here, the colors of the dots represent the
regions: grey for anterior temporal, red for posterior temporal, blue for parietal and green
for frontal. Round and triangle dots show, respectively, the sites mapped during the first
and the second mapping. The solid dots represent observed sites and the transparent dots
represent the posterior medians of the imputed values for the missing sites. The imputed
values of the missing sites are shown in the clouds behind the corresponding posterior
medians. The legends on the top-left corner show the matching between the sites (i.e.,
M ir, i = 1, . . . , 22, r = 1, . . . , 4) that appeared most frequently in the posterior samples. One
can see that the posterior medians of the imputed sites are very close to the matched observed
sites. Nevertheless, the clouds behind the posterior medians suggest some uncertainty in the
missing data imputation. For example, for subject 9, the 39-th site is an unobserved site. The
posterior median of the imputed values for this site overlaps the matched observed site and
the cloud behind it forms a circle centered at the posterior median. Another unobserved site
for the same subject (the 42-th site), however, has a shift from the matched observed site. The
majority of the cloud centered at the matched observed site with a few exceptions behind other
observed sites (i.e., the 40-th and 41-th sites). This reveals how the uncertainty in imputation
is affected by all observed sites that could be potential matches with the unobserved site.
Moreover, the way the sites matching to each other is intuitive: the sites mapped in the first
mapping are most likely to match the closest sites mapped in the second mapping.
3.4 Conclusion
We propose a Bayesian hierarchical model with augmented MCMC posterior sampling pro-
cedure to evaluate the variability of language localization for patients with resections in the
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language dominant cortex over a wide range of time periods. Our model is capable in handling
unequal numbers of sites mapped during the mappings and provides matching between the
sites using a probabilistic approach. Our model suggests substantial stability in the location of
language sites identified as essential for object naming with Electrical Stimulation Mapping
in patients undergoing repeat epilepsy surgery over a mean interval of 8.35 years with a range
of 1 to over 20 years. The average variability in these language sites are within 1cm and
consistent over different regions in the brain. This finding is similar to the subjectively stable
localization previously reported for adolescent epilepsy patients undergoing repeat mapping
(Ojemann et al. 2003, Serafini et al. 2013). Our analysis also demonstrates that the variability
in language localization is lower for patients who had an elapse less than 7 years than those
greater than, suggesting that change in the language localization gradually increases in dis-
tance and spread as the elapse between the two consecutive mappings increases. Further, by
adding one more set of the matching and missing variables, the model is readily extended to
the case where certain subjects have mappings on more than two occasions .
One additional thing to notice from the posterior sampling of the matching is that for
patient 21, both sites 91 and 92 in the first mapping match to site 92 in the second mapping
with highest frequency, and for patient 22, both sites 95 and 96 in the first mapping are most
likely to match to site 96 in the second mapping. This is due to the (almost) symmetric
geometric pattern of these sites. For example, for patient 22, there is an equal chance for site
95 and 96 in the first mapping to match site 94 and 96, or 96 and 94 in the mapping. However,
when one of them in the first mapping does not match to either 94 or 96, the other always has
a higher chance to match to 96 than to 94, and so both of them have higher chance to match
to 96 than the other sites. This is the same for patient 21. In order to solve this problem and
produce a better visualization of the matching, we eliminated the possibility of site 92 in the
first mapping to match site 91 in the second mapping, and site 95 in the fist mapping to match
site 96 in the second mapping. By doing so, all sites matched to unique corresponding sites.
84





































Figure 3.5: Visualization of imputed values and matching for Patient 1. The colors of the dots
represent the regions: grey for anterior temporal, red for posterior temporal, blue for parietal and
green for frontal. Round and triangle dots represent, respectively, the sites mapped during the first
and second mapping. The solid dots represent observed sites and the transparent dots represent the
posterior medians of the imputed values for the missing sites. The imputed values of the missing sites
are shown in the clouds behind the corresponding posterior medians.
Eliminating these possibilities does not change the posterior distributions of σr, r = 1, . . . , 4,
a and b.
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Figure 3.6: Visualization of imputed values and matching for Patient 2.
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Figure 3.7: Visualization of imputed values and matching for Patient 3.
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Figure 3.8: Visualization of imputed values and matching for Patient 4.
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Figure 3.9: Visualization of imputed values and matching for Patient 5
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Figure 3.10: Visualization of imputed values and matching for Patient 6
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Figure 3.11: Visualization of imputed values and matching for Patient 7
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Figure 3.12: Visualization of imputed values and matching for Patient 8
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Figure 3.13: Visualization of imputed values and matching for Patient 9
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Figure 3.14: Visualization of imputed values and matching for Patient 10
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Figure 3.15: Visualization of imputed values and matching for Patient 11
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Figure 3.16: Visualization of imputed values and matching for Patient 12
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Figure 3.17: Visualization of imputed values and matching for Patient 13
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Figure 3.18: Visualization of imputed values and matching for Patient 14
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Figure 3.19: Visualization of imputed values and matching for Patient 15
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Figure 3.20: Visualization of imputed values and matching for Patient 16
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Figure 3.21: Visualization of imputed values and matching for Patient 17
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Figure 3.22: Visualization of imputed values and matching for Patient 18
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Figure 3.23: Visualization of imputed values and matching for Patient 19
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Figure 3.24: Visualization of imputed values and matching for Patient 20
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Figure 3.25: Visualization of imputed values and matching for Patient 21
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Figure 3.26: Visualization of imputed values and matching for Patient 22
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Chapter 4
A note about appropriate background
selection in disproportionality analyses of
spontaneous drug safety reports
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4.1 Introduction
Prior to regulatory authorization, pharmaceutical companies conduct clinical trials of increas-
ing scope and complexity culminating in large-scale randomized, controlled trials. After
regulatory authorization, surveillance schemes based on spontaneous reporting system (SRS)
databases represent one of the cornerstones for the detection and evaluation of drug hazards.
The precise details of each SRS differ in terms of size and scope, statutory reportingmandates,
surveillance selectivity or intensity, and organizational structure. Prominent SRSs include
the FDA Adverse Event Reporting System (FAERS) of the United States Food and Drug
Administration (FDA), the Yellow Card Scheme of the Medicines and Healthcare Products
Regulatory Agency (MHRA), and the international pharmacovigilance program of the World
Health Organization (the WHO Uppsala Monitoring Center). These systems were created to
provide warnings of possible safety problems that would be difficult to detect during clinical
drug development due to power limitations, constricted range of demographics, exclusion
of patients with extensive co-morbid illnesses and co-medications, and limited duration of
follow-up. SRSs are often employed comparatively with other drugs (and without) to assist
in characterizing potential risks.
The first step in the SRS process is the submission of case reports of suspected adverse
drug reactions and/or adverse events to pharmaceutical companies and health authorities.
Although legally required in some countries, there is de facto voluntary reporting for all but
pharmaceutical manufacturers. The literature surveying the factors that influence reporting
behavior is extensive (Gibbons et al. 2010). Algorithmic methods have emerged to identify
signals in SRS databases. These include disproportionality analyses, sequential probability
ratio tests, and multiple regression. Most of the practical experience to date has been
with so called disproportionality analyses. While the precise operational details of each
disproportionality algorithm vary, they all calculate surrogate observed-to-expected ratios in
which the reporting experience of each reported Drug-Event Combination (DEC) is compared
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to the background reporting experience across all other drugs using an independence model.
Head-to-head comparisons of drugs are also not uncommon. In the appropriate clinical
context, DECs that stand out statistically against the background reporting experience merit
special attention.
4.2 Disproportionality methods
Disproportionality analysis methods for drug safety surveillance comprise the most widely
used class of analytic methods for signal detection in SRSs. These methods include the
DuMouchel’s Bayesian multi-item gamma-Poisson shrinker (MGPS) (DuMouchel 1999, Du-
Mouchel and Pregibon 2001), the Bayesian confidence propagation neural network (BCPNN)
(Bate 2007), proportional reporting ratios (PRR) (Evans et al. 2001), and reporting odds
ratios (ROR). The methods search SRS databases for potential signals, focusing on low-
dimensional projections of the data, specifically 2-dimensional contingency tables. Table 4.1
shows a fictitious table.
Table 4.1: A fictitious 2-dimensional projection of an SRS database onto a particular drug (drugi)
and a particular adverse event (AEj). The cells count the numbers of the reports in the SRS database
that involve (or do not involve) drugi and/or AEj . AE=adverse event.
AE j = Yes AE j = No Row total
Drugi = Yes w00 = 20 w01 = 100 w0+ = 120
Drugi = No w10 = 100 w11 = 980 w1+ = 1080
Column total w+0 = 120 w+1 = 1080 w++ = 1200
The basic task of a disproportionality method is then to rank these tables in order of
“interestingness”. Different disproportionality methods focus on different statistical measures
of association as their measure of interestingness. MGPS focuses on the “reporting ratio”
(RR). The observed RR for the drug i-adverse event j combination is the observed number
of occurrences of the combination (20 in Table 4.1) divided by the expected number of
occurrences under a model of independence (12 in this example). Thus the observed RR
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for this example is 20/12 or 1 2/3; this combination occurred about 67% more often than
expected.
In the SRS context, however, the count in the w00 cell is often small, leading to substantial
variability (and hence uncertainty about the true value of the measure of association) despite
the often large numbers of reports overall. PRR andRORdo not directly address the variability
issue whereas MGPS and BCPNN adopt a Bayesian approach to address the issue.
MGPS and its predecessor GPS are widely used methods and they provide a singular
example of large-scale Bayesian shrinkage in routine use by regulators and pharmaceutical
manufacturers worldwide. GPS proceeds as follows. Let w00(i, j) denote the w00 entry for
the 2 × 2 table for the i-th drug and the j-th adverse event. Assume that each w00(i, j) is
a draw from a Poisson distribution with mean µ(i, j). Let λ(i, j) = µ(i, j)/E(i, j), where
E(i, j) = w0+(i, j)w+1(i, j)/w++(i. j), i.e., the expected value of w00(i, j) under an indepen-
dence assumption, and is assumed to be known. The goal is to estimate these λ(i, j)’s. GPS
assumes that these λ(i, j)’s arise from a particular 5-parameter prior distribution, namely a
mixture of two gamma distributions. GPS adopts an empirical Bayes (EB) approach and
chooses the five hyper-parameters to maximize the marginal likelihood. Commonly reported
summary statistics include the geometric mean of the posterior distribution for each λ(i, j)
or the fifth percentile of the posterior (i.e.,“EBGM” and “EB05” respectively). For further
details see DuMouchel (1999) and Madigan (1999).
4.3 The choice of background: the Pioglitazone example
Pioglitazone is a thiazolidinedione drug used to treat diabetes. Concerns about a possible
causal association between pioglitazone and bladder cancer have existed at least since 2011
(Medical-reference 2011). Table 4.2 shows an actual 2×2 table for the drug pioglitazone and
the adverse event of bladder cancer from AERS database as of 2005. Here, the cell counts
are the number of reports that mention specific DECs. Due to multiple drugs and/or adverse
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events recorded in individual reports, there are altogether 25million DECs (i.e., the total count
w++ in Table 4.2), despite the fact that there are 2.7 million distinct reports. As is typically
the case, the number of reports included in row 2 of the table (the “background”) vastly
outnumbers the number of reports in row 1, that is, reports mentioning the drug pioglitazone.
Table 4.2: 2 × 2 AERS table for pioglitazone and bladder cancer as of 2005.
Bladder cancer= Yes Bladder cancer= No Row total
Pioglitazone= Yes w00 = 16 w01 = 33, 629 w0+ = 33, 625
Pioglitazone= No w10 = 3, 512 w11 = 25, 430, 705 w1+ = 25, 434, 217
Column total w+0 = 3, 528 w+1 = 25, 464, 314 w++ = 25, 467, 842
Table 4.3 shows the actual 2 × 2 table for the drug metformin and the adverse event of
bladder cancer. Like pioglitazone, metformin is indicated for diabetes. Again, the number of
reports included in row 2 of the table vastly outnumbers the number of reports in row 1, in
this case, reports mentioning the drug metformin.
Table 4.3: 2 × 2 AERS table for metformin and bladder cancer as of 2005.
Bladder cancer= Yes Bladder cancer= No Row total
Metformin= Yes w00 = 11 w01 = 109, 406 w0+ = 109, 417
Metformin= No w10 = 3, 517 w11 = 25, 354, 908 w1+ = 25, 358, 425
Column total w+0 = 3, 528 w+1 = 25, 464, 314 w++ = 25, 467, 842
Table 4.4 shows the RR, EBGM, and EB05 statistics corresponding to the above piogli-
tazone and metformin tables (i.e., Table 4.2 and 4.3.) Using the standard signaling threshold
of 2, a signal of disproportionate reporting exists for pioglitazone and bladder cancer using
EBGM (2.72 in Table 4.5), while no such signal exists for metformin. Table 4.5 shows the
same statistics but now using metformin as the “background” for pioglitazone and vice versa
(i.e., new 2×2 tables consisting of row 1 only from Table 4.2 and 4.3). Using the standard
signaling threshold for EBGM and EB05, remarkably, no signal exists for pioglitazone when
metformin is used as the background, despite the fact that the conventional EBGM for piogli-
tazone and bladder cancer is more than quadruple that of metformin. Thus, even though no
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signal exists for metformin and bladder cancer, using metformin as the background makes the
EBGM signal for pioglitazone disappear.
Table 4.4: Disproportionality analysis for drug pioglitazone/metformin and adverse event of bladder
cancer using all non-pioglitazone/metformin drugs as background from AERS database as of 2005.
Drug w00 E RR EB05 EBGM
Pioglitazone 16 4.65 3.43 1.78 2.72
Metformin 11 15.16 0.73 0.44 0.72
Table 4.5: Disproportionality analysis for drugs pioglitazone/metformin and adverse event of bladder
cancer using metformin/pioglitazone as background from AERS database as of 2005.
Drug w00 E RR EB05 EBGM
Pioglitazone 16 6.35 2.52 0.96 1.3
Metformin 11 20.65 0.53 0.42 0.78
Figure 4.1 shows the posterior distributions from the disproportionality analysis for pi-
oglitazone (shown by red curve) and metformin (blue curve) and the adverse event of bladder
cancer using all other drugs as background (panel a) versus using metformin and pioglitazone
as background respectively (panel b). After changing the background to a single reference
drug, the posterior distribution for pioglitazone moved to the left, resulting in smaller values
of EBGM and EB05 statistics.
4.4 The choice of background: the general case
In the AERS database as of 2005, for all DECs, 93.9% of such background changes (i.e.,
using a single drug instead of all drugs as the background) lead to smaller values of the RR.
Figure 4.2 shows the distribution of RR pairs calculated using the two kinds of background
for a random sample of 100 drug pairs for each adverse event in AERS. The horizontal axis
represents the background using all other DEC’s in the database and the vertical axis shows
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Figure 4.1: Posterior distributions for pioglitazone and metformin using all other drugs as background
(panel a)VS onlymetformin and pioglitazone as background (panel b). Red lines represent pioglitazone
and blue lines represent metformin. Dashed lines show EBGM and EB05 statistics. Gray and white
delineate the standard signaling threshold of 2.
squares show the proportion of RR pairs lying in each grid on this 2-dimensional space. We
can see from Figure 4.2 that the majority of the RR pairs lie below the 45-degree line, such
that changing the background to a single drug leads to a smaller value of the RR.
The decreased RR’s have two effects on the posterior distribution of the disproportionate
analysis: (1) The posterior distribution for a certain DECmoves to the left as its RR decreases,
fixing the observed cell count w00 and the hyper-parameters fitted by the model; (2) In
(M)GPS’s empirical Bayes framework, the reduced RR values for the majority of the DECs
lead to change in the estimation of the hyper-parameters, which in turn pushes the posterior
distribution further to the left. As a result, the EBGM and EB05 statistics become smaller,
masking the signal of risk in the drug if the signaling threshold is set to the standard value of
2.
Table 4.6 illustrates the condition for the RR to decrease. Using our example in Section
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Figure 4.2: Distributions of RR’s using the two backgrounds for all DEC’s in AERS database as of
2005. The horizontal axis represents the background using all other drugs in the database and the
vertical axis shows that using only one reference drug (both on the log scale). The red-to-pink squares
show the proportion of RR pairs lying in each grid on this 2-dimensional space. A 45-degree line is
also displayed.
4.3, the conventional disproportionality method considers the first row (i.e., pioglitazone) and
combines the second and third rows, whereas the method using metformin as background
considers only the first 2 rows. Let A = w00 + w0′0 and B = w01 + w0′1. One can show that
RR decreases if and only if the ratio (A/B)/(w10/w11) > 1 (in our example, this ratio equals
to 1.37). Since w11 is overwhelmingly big compared to other numbers in the table, this ratio
is very likely to be greater than 1. Therefore, choosing the background of only one reference
drug and carrying out head-to-head disproportionality analysis results in a very high chance
to underestimate the true potential hazard of the drugs if such a hazard exists.
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Table 4.6: Illustration of the condition under which RR decreases, using pioglitazone and metformin
example in ARES database as of 2005.
Bladder cancer= Yes Bladder cancer= No Row total
Pioglitazone w00 = 16 w01 = 33, 629 w0+ = 33, 625
Metformin w0′0 = 11 w0′1 = 109, 406 w0′+ = 109, 417
All other drugs w10 = 3, 501 w11 = 25, 321, 279 w1+ = 25, 324, 800
Column total w+0 = 3, 528 w+1 = 25, 464, 314 w++ = 25, 467, 842
4.5 Discussion
Post-marketing drug safety surveillance based on large-scale spontaneous reporting system
(SRS) databases is a useful approach to detect and evaluate potential drug risks after they
are approved by regulatory authorization. Disproportionality analysis is a frequently applied
technique in such context. Although employing the method in a comparative way to a single
existing drug has been reported in the literature (Qizilbash et al. 2012), this note shows that
the head-to-head comparison using a single drug as the background has a masking effect on
the signaling of adverse events. In order to detect risk signals from large-scale databases
such as AERS, it is thus not recommended to use a single reference drug as background
in disproportionality analysis, and the standard way of involving all DECs from the entire
database represents a more appropriate background selection.
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Conclusion
In healthcare practice, the sample size for certain types of patients may be too small to permit
accurate conclusions. For example, in personalized treatment, medical decisions are often
made using limited historical information. Bayesian methods of inference allow borrowing
information from other patients with more historical information, leading to more accurate
understanding of the medical condition and more effective treatment of individual patients.
In neuroscience, the complex structure of the data necessitates the use of flexible modeling
strategies. In this dissertation, we propose Bayesian modeling strategies to address various
methodological challenges in the statistical analysis of data in neuroscience and medicine.
We first construct a sparse Bayesian hierarchical VAR model for studying resting state
functional connectivity using multi-subject multi-session fMRI data. Our model extends
existing multi-subject single subject Bayesian VAR models to allow for the decomposition of
functional connectivity into group, subject, and session components. As demonstrated in our
simulations, our model improves on two stage procedures for connectivity metrics in which
single subject models are estimated in a first step, then pieced together in a second step. The
simulations also indicate that our model estimates are quite accurate across a wide variety of
conditions, including small samples. Further, our model allows us to systematically address
an important question: Is the major portion of variability in resting state neural activity due to
differences between subjects or differences within subjects? Analyzing data from 50 subjects
in the Human Connectome Project, we find greater variability between subjects than within
subjects across sessions separated by a day, suggesting the major source of differences in
human brain connectivity is due to differences among subjects. In future work, we intend to
increase the computational capacity of the model. Using parallel computing techniques such
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as the consensus Monte Carlo algorithm (Scott et al. 2013) in conjunction with our parameter
expanded Gibbs sampler will allow us to work with more ROI’s and subjects. Increasing
the number of ROI’s will allow us to 1) subdivide existing regions and assess whether the
connections among regions we have discovered require additional refinement, and 2) extend
the number of regions under investigation to a whole brain ROI model, allowing us to
potentially discover new connections between regions and networks. The ability to handle
larger samples will allow us to estimate parameters more reliably. It will also allow us to
better differentiate among types of individuals, e.g., healthy controls and autistic individuals,
and more generally allow for the exploration of sub-group differences, e.g., men and women.
We then applied the same hierarchical VAR model to data from patient diary databases,
focusing on patient-level prediction ofmedical conditions using posterior predictive sampling.
Our reanalysis of the data used in previous diary studies demonstrates the superiority of our
model for patient level prediction: the advantage of partial pooling among subjects in the
Bayesian model is substantial for datasets where certain patients have only a small number
of observations. Our model also provides inference about population-level coefficients and
between-subject heterogeneity, something that has not been systematically investigated in
previous work.
We also propose a novel Bayesian model for repeat Electrical Stimulation Mappings
(ESM) to quantify the change in localization of the brain regions responsible for language
function over an extended period of time. We adopt an augmented Markov Chain Monte
Carlo (MCMC) posterior sampling procedure, which not only evaluates the variability in
language localization, but also imputes unobserved sites and provides a probabilistic solution
for matching sites across occasions. Our analysis suggests that language localization is
generally stable over time, but the variability in language localization gradually increases in
distance and spread as the time between the two consecutive mappings increases.
Finally, we apply Bayesian disproportionality analyses to spontaneous reporting system
117
(SRS) databases. Using an empirical approach, we found that using the background of a
single reference drug, as opposed to the original background of all other drugs in the database,
generally results in smaller disproportionality metrics, masking the true safety signaling. We
therefore emphasize the appropriate use of Bayesian methods and interpretation of results to
avoid unwarranted conclusions and poor decision making.
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